Entries |
Document | Title | Date |
20080206216 | Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules - The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 08-28-2008 |
20080206217 | Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules - The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 08-28-2008 |
20080206218 | Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules - The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 08-28-2008 |
20080213237 | Antigen Specific Lymphocytes, Compositions Thereof, and Methods for Isolation and Preparation Thereof - The invention relates to a method for the isolation of T cell lymphocyte, preferably, CD8 | 09-04-2008 |
20080233095 | METHOD FOR OBTAINING ANTIGEN-SPECIFIC TR1 REGULATORY LYMPHOCYTES - The invention relates to a method for preparing antigen-specific Tr1 regulatory lymphocytes. The inventive method involves the use of artificial antigen-presenting cells, expressing a molecule from the HLA class II system and a human LFA-3 molecule and expressing none of the B7-1, B7-2, B7-H1, CD40, CD23 or ICAM-1 costimulation molecules. | 09-25-2008 |
20080248011 | Methods for Isolating Monocytes - The present invention provides HIDE1 as novel monocyte markers. Since HIDE1 are membrane proteins, monocytes can be specifically detected by using antibodies that bind to HIDE1. Further, HIDE1-positive monocytes can also be collected from peripheral blood or the like using a cell sorter, magnet, or such. Monocytes that can be prepared based on the present invention are useful in cell immunotherapy. | 10-09-2008 |
20080260710 | Method for Suppressing Surgical Site Infection and Column to be Used for the Method - An object of the present invention is to provide a method for suppressing surgical site infections (SSI) that have occurred at extremely high incidence rates at the time of surgical operations and particularly surgical operations on digestive system organs, and to provide a column to be used for the method. According to the present invention, a method is provided for suppressing surgical site infections, which comprises the steps of: (a) administering a chemotherapeutic drug for treating and/or preventing a surgical site infection; and (b) collecting blood from a surgical subject and removing leukocytes that comprise neutrophils from the blood during or within 24 hours after surgical operation, and then returning the blood from which the leukocytes have been removed to the surgical subject. The present invention also provides a column for blood circulation which is filled with a carrier having affinity for leukocytes comprising neutrophils, which is used for suppressing a surgical site infection during or within 24 hours after surgical operation on a digestive system organ. | 10-23-2008 |
20080267934 | Use of Apoptotic Cells Ex Vivo to Generate Regulatory T Cells - Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004). | 10-30-2008 |
20080267935 | AraC in combination with a cytokine-secreting cell and methods of use thereof - The present invention provides improved method of cancer therapy in a mammal. More particularly, the invention is concerned with systems comprising cytosine arabinoside (AraC) and a cytokine-expressing cancer immunotherapy composition and methods of administering the combination to cancer patients in order to generate an immune response against the cancer and provide treatment with therapeutic efficacy that is an improvement relative to administration of AraC or the cytokine-expressing cancer immunotherapy composition alone as a monotherapy. | 10-30-2008 |
20080279833 | LAMINATE SHEET ARTICLES FOR TISSUE REGENERATION - The invention is to articles of extracellular matrix. The articles comprise one or more sheets of mammalian extracellular matrix laminated together. A single sheet can be folded over and laminated on 3 sides. Two or more sheets can be laminated to each other at their edges. The sheets can further encase a composition comprising a cell or cells, such as for example, a stem cell. A single sheet can be folded over to encase a composition, or rolled to encase a composition with lamination at either end of the roll, for example. The invention also includes methods of using these articles to regenerate tissue at tissue defects, or heal wounds in damaged tissue. | 11-13-2008 |
20080279834 | Methods and Reagents for Identifying/Isolating T Regulatory (Treg) Cells and for Treating Individuals - An affinity ligand is reactive to the GARP protein may be capable of binding to an extracellular domain of GARP protein expressed on regulatory T (Treg) cells. The affinity ligand may be an antibody and may be used to identify Treg cells. A method comprises providing a blood sample from a subject and determining the amount of Treg cells in that sample. A composition containing Treg cells may be administered to an individual to suppress effector T cell activity in the individual. A composition containing an affinity ligand capable of binding to a GARP domain may be administered to an individual to suppress Treg cell activity and increase effector T cell activity in the individual. A kit for detecting Treg cells may include an affinity ligand reactive with mammalian GARP protein. | 11-13-2008 |
20080279835 | Method of Stem Cell Therapy for Cardiovascular Repair - A method of treating acute myocardial infarction has the steps of providing human umbilical cord blood cells (HUCBC); and administering the HUCBC to the individual with the acute myocardial infarction at particular time intervals after said myocardial infarction. Preferably the intervals are about one to about three hours or about 12 to about 48 hours after the acute myocardial infarction. | 11-13-2008 |
20080279836 | METHOD OF MAKING A CELL THERAPY FORMULATION - Ex-vivo prepared T-cells are harvested from cell culture conditions and formulated in medium suitable for infusion. The formulation is made by labeling the cells with one or more agents which have reactivity for T-cell surface moieties capable of delivery activation signals upon cross-linking and mixing the labeled cells with biodegradable nanospheres or microspheres coated with a material capable of cross-linking the agents attached to the T-cell surface moieties. Alternatively, the formulation may be made by mixing a population of T-cells with biodegradable nanospheres or microspheres coated with a first material and one or more second materials. The first material binds the second material and the second material has reactivity for surface moieties on the T-cells and the interaction of the second materials with the T-cells causes the activation of the T-cells. In either method, the mixture of T-cells and biodegradable spheres are suspended in a medium suitable for infusion, and the mixture is packaged in a container. | 11-13-2008 |
20080292605 | Materials for stimulation of hematopoiesis by ex vivo activated cells - A protocol of activating and administering human blood cells so that bone marrow histology and/or blood cell counts of patients suffering from a plastic anemia approach normal. The protocol includes culturing the blood cells in the presence of a cytokine and an ionophore. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. | 11-27-2008 |
20080305091 | Poly-Epitope Peptide Derived from Thymidylate Synthase Having Immunological and Anti-Tumour Activity - The present invention concerns a peptide having anti-tumour activity and its related pharmaceutical compositions. In particular, the invention concerns a peptide with anti-tumour preventive and therapeutic activity, also in combination with other known anti-tumour compounds such as, for example, 5-fluorouracil. | 12-11-2008 |
20080305092 | Methods of treating autoimmune disease via CTLA-4IG - The method of immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of activated T cell lymphokine production occurs upon stimulatory binding of the CD28 surface receptor molecule, even in the presence of conventional immunosuppressants. Inhibition of CD28 receptor binding to an appropriate stimulatory ligand or inactivation of the CD28 signal transduction pathway through other means down-regulates CD28-pathway related T cell lymphokine production and its resulting effects. | 12-11-2008 |
20080311098 | COMPOUNDS AND METHODS FOR MODULATING THE IMMUNE RESPONSE AGAINST ANTIGENS - Chimeric nucleic acids and polypeptides comprising an antigen or an epitope thereof are described, as well as compositions and methods to increase the presentation of an antigen or epitope by MHC class II molecules and to modulate the immune response. | 12-18-2008 |
20080317724 | Micropatterned T cell stimulation - The invention relates to methods of expanding, stimulating or activating T cells by modulating the spatial organization of signal molecules presented to the T cells. | 12-25-2008 |
20090017000 | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies - Methods of processing inactivated artificial antigen presenting cells (aAPCs) and artificial antigen presenting cells with specificity for selected antigenic peptides are described, including their generation and use in cell therapy compositions comprising activated cytotoxic T lymphocytes. Inactivated aAPCs are advantageously generated through crosslinking, such as via a photoreaction involving a psoralen derivative and UVA irradiation. | 01-15-2009 |
20090060890 | SELECTIVE CYTOPHERESIS DEVICES AND RELATED METHODS THEREOF - The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action. | 03-05-2009 |
20090074736 | IMPLANTABLE PREPARATIONS COMPRISING GLOBIN, PROCESS FOR THEIR PRODUCTION, AND USES - Preparations comprising, especially, globin that is insoluble at neutral pH, and therefore at physiological pH, in which the globin has been obtained from whole blood by depigmentation in a medium that extracts or dissolves the haem but leaves the globin and the other constituents of proteinic nature in a substantially undissolved state, a process for the production of those preparations, and uses, especially for the filling, healing or regeneration of tissues, especially for chronic wounds and osseous healing or regeneration. | 03-19-2009 |
20090081175 | Method for Treating Disseminated Cancer - The present invention discloses an immunotherapeutic method for treating a patient suffering from a disseminated cancer by administering expanded tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes obtainable from one or more metastasis-draining lymph nodes (metinel nodes) draining a metastasis. The method comprises identification of one or more metinel lymph nodes in a patient, resection of the one or more nodes and, optionally all or part of the metastases, isolation of metastasis-reactive T-lymphocytes from said lymph nodes, in vitro expansion of said metastasis-reactive T-lymphocytes, and administration of the thus obtained T-lymphocytes to the patient, wherein the T-lymphocytes are CD4+ helper and/or CD8+ T-lymphocytes. | 03-26-2009 |
20090081176 | Cure for the human immunodeficiency virus - A method whereby a cure is found for the Human Immunodeficiency Virus (HIV) by rebuilding and stimulating the infected individual's immune system. | 03-26-2009 |
20090098095 | METHOD OF EXPANDING DOUBLE NEGATIVE T CELLS - A method of expanding double negative T cells in culture is described. The method comprises (a) providing a starting sample comprising DN T cells or precursors thereof; (b) substantially depleting CD8 | 04-16-2009 |
20090104170 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS - The invention generally relates to a composition comprising an enriched NK cell population. The invention further relates to a method of treating a solid tumor or a hyperproliferative disorder by administering the enriched NK cell population to a mammalian subject in need thereof. | 04-23-2009 |
20090117089 | GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NK T CELLS - This invention relates to immunogenic compounds which may serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses. | 05-07-2009 |
20090123442 | EXPANDED NK CELLS - The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment. | 05-14-2009 |
20090123443 | Method for Treating Colon Cancer - The present invention discloses an immunotherapeutic method for treating patients suffering from colon cancer, by administering expanded tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes obtainable from one or more sentinel or metinel lymph nodes draining a tumour in the colon or a metastasis arising from a tumour in the colon. The present invention provides a new effective method for treating colon cancer and metastatic colon cancer, without adverse side effects associated with the known treatments. The method comprises identification of in a patient one or more sentinel and/or metinel lymph nodes draining a tumour in the colon or a metastasis from a tumour in the colon, resection of the one or more nodes and, optionally all or part of the tumour or metastasis, isolation of tumour-reactive T-lymphocytes from said lymph nodes, in vitro expansion of said tumour-reactive T-lymphocytes, and administration of the thus obtained tumour-reactive T-lymphocytes to the patient, wherein the T-lymphocytes are CD4+ helper and/or CD8+ T-lymphocytes. | 05-14-2009 |
20090130074 | PREPARATION OF ANTIGEN-PRESENTING HUMAN GAMMA DELTA T CELLS AND USE IN IMMUNOTHERAPY - Cytotoxic αβ T cells form an essential component in immunity to infections and tumors, and are also implicated in host defense against these challenges. The present disclosure demonstrates the ability of activated γδ T cells to cross-present exogenous antigens to CD8 | 05-21-2009 |
20090136470 | REGULATORY T CELLS AND METHODS OF MAKING AND USING SAME - Methods of stimulating or increasing differentiation to regulatory T cells, cultures of regulatory T cells and methods of reducing or decreasing an immune response, inflammation or an inflammatory response, among other things, are provided. Methods include, among other things, contacting blood cells or T cells with an amount of TGF-beta or a TGF-beta analogue and a retinoic acid receptor agonist, or an amount of a retinoid X receptor (RXR) or peroxisome proliferator activated receptor-gamma (PPARgamma) agonist, sufficient to stimulate or increase differentiation to regulatory T cells. Cultures of regulatory T cells include T cells that express a marker associated with regulatory T cells, such as cultures in which regulatory T cells represent, for example, 30% or more of the total number of cells in the culture. | 05-28-2009 |
20090142316 | Use of Dendrimers to Stimulate Cell Growth - The present invention relates to the use of dendrimers with monophosphonic or bisphosphonic terminations in order to stimulate the growth of cell cultures or to activate cells in culture. | 06-04-2009 |
20090142317 | PROCESS FOR REDUCING EFFECTS OF GRAFT VERSUS HOST DISEASE USING EX VIVO EXPANDED CD4+CD25+ REGULATORY T CELLS - Disclosed in this specification is a process for producing ex vivo expanded CD4+CD25+ regulatory T cells. The process includes the steps of extracting a sample that includes peripheral blood mononuclear cells from a human donor. The extracted cells include a certain number of cells which are CD4+CD25+ regulatory T cells. The relative population of the CD4+CD25+ regulatory T cells is enhanced such that the Treg cells constitute the majority of the cells in the sample. Thereafter, the population of the enriched Treg cells, that may include third-party derived Treg cells, is expanded to produce a clinically meaningful population of cells for use in the treatment of GVHD. | 06-04-2009 |
20090142318 | METHOD TO EXPAND nTREG CELLS USING p70 S6 KINASE ANTAGONIST - Disclosed in this specification is a method to promote the growth of CD4+CD25Foxp3+ nTreg cells in a culture while treating the culture with a p70 S6 kinase inhibitor. The resulting cells are useful in the treatment of immune-related diseases. | 06-04-2009 |
20090142319 | METHOD TO EXPAND nTREG CELLS USING PI-3K ANTAGONIST - Disclosed in this specification is a method to promote the growth of CD4+CD25Foxp3+ nTreg cells in a culture while treating with a PI-3K antagonist. The resulting cells are useful in the treatment of immune-related diseases. | 06-04-2009 |
20090142320 | METHOD TO MINIMIZE IL-17 PRODUCTION DURING nTREG CELL EXPANSION - Disclosed in this specification is a method to promote the growth of CD4+CD25Foxp3+ nTreg cells in a culture while minimizing the production of IL-17. The resulting cells are useful in the treatment of immune-related diseases. | 06-04-2009 |
20090162334 | PRODUCTION AND USE OF REGULATORY T CELLS - An ex vivo method for generating a population of Treg capable of suppressing rejection of an organ or tissue transplant from a donor animal, comprises culturing CD4 | 06-25-2009 |
20090175838 | METHODS OF MODULATING IMMUNE FUNCTION - The invention relates to methods for modulating the immune function through targeting of CLIP molecules as well as gamma delta T-cells. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject. | 07-09-2009 |
20090191173 | Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1 - A method for inducing and enhancing neurogenesis and/or oligodendrogenesis from endogenous as well as from exogenously administered stem cells comprises administering to an individual in need thereof an agent selected from the group consisting of Copolymer 1, a Copolymer 1-related polypeptide, a Copolymer 1-related peptide, and activated T cells which have been activated by Copolymer 1, a Copolymer 1-related polypeptide, or a Copolymer 1-related peptide. The method is particularly useful for stem cell therapy in combination with the agent. | 07-30-2009 |
20090202506 | EX-VIVO PRIMING FOR GENERATING CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR NON-TUMOR ANTIGENS TO TREAT AUTOIMMUNE AND ALLERGIC DISEASE - Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo. | 08-13-2009 |
20090208471 | Isolation and Use of Human Regulatory T Cells - The present invention provides a new method for isolating and enriching human regulatory T cells. The enriched cells are useful in the treatment of autoimmune disease. | 08-20-2009 |
20090220472 | Method for Treating Malignant Melanoma - The present invention discloses an immunotherapeutic method for treating patients suffering from malignant melanoma, by administering expanded tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes obtainable from one or more sentinel or metinel lymph nodes draining a malignant melanoma or a metastasis arising from malignant melanoma. The present invention provides a new effective method for treating malignant melanoma and metastatic malignant melanoma, without adverse side effects associated with the known treatments. The method comprises identification of in a patient one or more sentinel and/or metinel lymph nodes draining a malignant melanoma or a metastasis there from, resection of the one or more nodes and, optionally all or part of the tumour or metastasis, isolation of tumour-reactive T-lymphocytes from said lymph nodes, in vitro expansion of said tumour-reactive T-lymphocytes, and administration of the thus obtained tumour-reactive T-lymphocytes to the patient, wherein the T-lymphocytes are CD4+ helper and/or CD8+ T-lymphocytes. | 09-03-2009 |
20090220473 | ADIR RELATED POLYMORPHISMS AND APPLICATIONS THEREOF - The invention relates to the field of stem cell transplantations, immunotherapy and prophylaxis of neoplastic disease. Provided are peptides comprising an amino acid sequence encoded by an open reading frame as present in the nucleotide sequence of a transcript of a naturally occurring hADIR allele, wherein the amino acid sequence comprises a polymorphic MHC class I or II minor histocompatibility binding peptide. | 09-03-2009 |
20090257994 | Chimeric immunoreceptor useful in treating human cancers - The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human malignancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain. | 10-15-2009 |
20090297489 | Method for Expansion of Tumour-Reactive T-Lymphocytes for Immunotherapy of Patients with Cancer - The present invention discloses an improved method for expansion and activation of tumour-reactive lymphocytes, in particular CD4+ helper and/or CD8+ T-lymphocytes, which may be used for treating and/or preventing cancer. The method provides high numbers of tumour-reactive T-lymphocytes within a short time span and the possibility of directing development of tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes towards specific subpopulations. The method comprises a first phase of stimulating tumour-reactive CD4+ T helper and/or CD8+ T-lymphocytes with tumour-derived antigen together with at least one substance having agonistic activity towards the IL-2 receptor to promote survival of tumour-reactive CD4+ T helper and/or CD8+ T-lymphocytes; and a second phase of activating and promoting growth of tumour-reactive CD4+ T helper and/or CD8+ T-lympho-cytes, wherein the second phase is initiated when the CD25 cell surface marker (or IL-2R marker) is down-regulated on CD4+ T helper and/or CD8+ T-lymphocytes. | 12-03-2009 |
20090297490 | NOVEL HUMAN T-CELL POPULATION - The present invention has objects to provide a novel human T-cell population having both cytotoxic and immunosuppressive activities, and to a method for preparing the same. The above objects are attained by providing a human T-cell population which is obtainable by coculturing mononuclear cells, collected from human blood, with stroma cells and which has the following features:
| 12-03-2009 |
20090304657 | CHIMERIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides a chimeric T cell receptor (TCR) comprising a variable region of a human TCR and a constant region comprising at least an extracellular domain of a constant region of a non-human TCR, as well as functional variants thereof. The invention also provides polypeptides and proteins related to the inventive TCRs, as well as nucleic acids encoding the TCRs, polypeptides, or proteins, recombinant expression vectors, and host cells. Further provided are pharmaceutical compositions related to the inventive TCRs and methods of preventing or treating a disease, e.g., an infectious disease, cancer, in a host, methods of detecting a diseased cell in a host, and methods of improving the biological activity of a TCR. | 12-10-2009 |
20090304658 | METHOD OF PROLIFERATING LAK CELL - The present application aims at providing a treatment method effective for various cancers, immune deficiency diseases and infections, and a method of proliferating/activating cells associated therewith, which can be performed at such low costs that the methods can be applicable to nonhuman animals. | 12-10-2009 |
20090304659 | ANTI-CD8 ANTIBODIES BLOCK PRIMING OF CYTOTOXIC EFFECTORS AND LEAD TO GENERATION OF REGULATORY CD8+ T CELLS - The present invention includes compositions and methods for inducing tolerance in a subject in need thereof comprising providing the subject with an effective amount of an anti-CD8 antibody sufficient in induce CD8 | 12-10-2009 |
20090304660 | G-CSF DERIVATIVE FOR INDUCING IMMUNOLOGICAL TOLERANCE - The invention relates to a method for inducing immunological tolerance, in particular transplantation tolerance, by administering a G-CSF derivative or biologically active fragment, homolog, or variant thereof, in particular peg-G-CSF, to a donor cell or a transplantation donor. The invention also relates to expanding and stimulating selected donor cells by administering a G-CSF derivative, preferably peg-G-CSF. The donor cells are preferably granulocyte-monocyte precursor cells and IL-10 secreting T cells. | 12-10-2009 |
20090311228 | TREATMENT OF INFLAMMATORY BOWEL DISEASE - A method of treating inflammatory bowel disease (IBD) comprises collecting regulatory T cells in an activated or non-activated state from a patient's sentinel lymph nodes draining bowel segments with or without IBD, optionally activating the cells by contacting them with a cytokine and an antigen extract obtained from an inflamed bowel segment, expanding the T cells in vitro, and re-infusing the expanded T cell to the patient. Also disclosed are methods for obtaining sentinel nodes, for expanding T cells, for re-establishing the T | 12-17-2009 |
20090311229 | Isolation and Identification of Cross-Reactive T Cells - Cross-reactive T cells recognizing both MBP | 12-17-2009 |
20090324566 | T-Cell Receptor and Nucliec Acid Encoding the Receptor - A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4 | 12-31-2009 |
20090324567 | Leukocyte Cell Banks - The invention relates to a novel form of leukapheresis (isolated leukapheresis), to processes and apparatus for carrying out isolated leukapheresis, to leukocyte cell banks created thereby and to various forms of therapy based thereon. | 12-31-2009 |
20100003228 | T-CELL VACCINE - An improved T-cell vaccine and methods of making the vaccine are described. The vaccine may be made by stimulating T-cells with all epitopes of an antigenic polypeptide that may be capable of stimulating autoreactive T cells. | 01-07-2010 |
20100015112 | Methods for the Induction of Professional and Cytokine-Producing Regulatory T Cells - The field of the invention is generally related to methods used for the induction of T cells with suppressive activity. More specifically, the methods are used to generate professional regulatory T cells and cytokine-producing T cells with enhanced suppressive activity. | 01-21-2010 |
20100015113 | GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein. | 01-21-2010 |
20100015114 | PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR EXPRESSION LEVEL AS AN INDEX OF ORGAN DAMAGE AND REGENERATION - The present invention relates to methods, reagents, and kits for assessing organ damage, such as damage due to ischemia reperfusion injury, in the course of a transplantation therapy and/or for assessing organ regeneration following transplantation therapy. The invention provides a method for determining an index of organ health in the course of transplantation therapy comprising measuring the expression level of peripheral-type benzodiazepine receptor (PBR) in the organ. Measuring the expression level of PBR is also useful for assessing the progress of organ regeneration in the course of transplantation therapy by comparing the index of organ health. The expression level of PBR may be used as a predictor of the outcome of transplantation therapy. | 01-21-2010 |
20100021447 | Medicament for Treating Problems Relating to Fertility and Pregnancy, and Autoimmune Diseases, and for Inducing an Immunological Tolerance in Transplant Patients, and Method for Producing Said Medicament - A medicament for treating pregnancy disorders or for inducing an immunological tolerance in patients with autoimmune diseases or transplantation processes, contains at least one each of a) a precursor hCG β subunit of the human choriongonadotropine (hCG) selected from hCG β6 according to SEQ ID NO 1 or SEQ ID NO 2 and hCG β7 according to SEQ ID NO 5 or a mature hCG β subunit selected from hCG β6 according to SEQ ID NO 3 or SEQ ID NO 4 and hCG β7 according to SEQ ID NO 6 or glycolised fragments of these sequences; and b) a precursor α subunit of hCG according to SEQ ID NO 9 or the mature α subunit of hCG according to SEQ ID NO 10 or glycolysed fragments of these sequences, wherein the β subunits and the α subunits are preferably used in equimolar quantities. | 01-28-2010 |
20100034793 | METHOD OF USING STROMA CELLS FROM CORD BLOOD TO EXPAND AND ENGRAFT NUCLEATED CELLS FROM CORD BLOOD - The invention features a method for expanding and engrafting nucleated cells, e.g., progenitor cells, such as hematopoietic cells, obtained from cord blood by co-culturing the nucleated cells with adherent stroma cells, e.g., mesenchymal stem/progenitor cells, also obtained from cord blood. | 02-11-2010 |
20100034794 | ENDOTHELIAL PROGENITOR CELL COMPOSITIONS AND NEOVASCULARIZATION - Methods and compositions are provided for inducing neovascularization in injured tissues with endothelial progenitor cells (EPCs). Mixtures of purified CD34+ endothelial progenitors and purified CD14+ monocytes, or products of an in vitro co-culture of purified CD34+ endothelial progenitor cells and purified CD14+ monocytes provide neovascularization after administration to a subject having a tissue injury, such as an ischemic injury. | 02-11-2010 |
20100040590 | Tumor-associated peptides binding to human leukocyte antigen (HLA) class II molecules - The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 02-18-2010 |
20100047220 | Substances - This invention provides a cell presenting at least one T cell receptor (TCR) anchored to the membrane by a transmembrane sequence, said TCR comprising an interchain disulfide bond between extracellular constant domain residues which is not present in native TCRs. | 02-25-2010 |
20100068192 | Method for Production of T Cell Population - A method for preparing a T cell population, wherein the T cell population expresses CD45RA and expresses at least one selected from the group consisting of CD62L, CCR7, CD27, and CD28, characterized in that the method comprises the step of culturing a cell population comprising a T cell, in the presence of fibronectin, a fragment thereof or a mixture thereof. | 03-18-2010 |
20100068193 | METHODS AND MATERIALS FOR THE GENERATION OF REGULATORY T CELLS - Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25− T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed. | 03-18-2010 |
20100068194 | COMPOSITION FOR IN VIVO TRANSPLANTATION FOR TREATMENT OF HUMAN CERVICAL CANCER COMPRISING MONONUCLEAR CELLS DERIVED FROM UMBILICAL CORD BLOOD - Provided is a composition for in vivo transplantation for the treatment of human cervical cancer, comprising mononuclear cells derived from umbilical cord blood and a pharmaceutically acceptable carrier. When the umbilical cord blood-derived mononuclear cells are transplanted in vivo, cervical cancer can be effectively treated. In particular, the mononuclear cells derived from the umbilical cord blood retain high differentiation and proliferation abilities and exhibit very low graft-versus-host (GVH) reactions which are side effects caused by transplantation, and thus, can be transplanted to many patients. | 03-18-2010 |
20100080784 | METHODS FOR TREATING CACHEXIA AND LYMPHOPENIA - Disappearance of a cell population, designated CD4 | 04-01-2010 |
20100092444 | PLATELET RICH PLASMA FORMULATIONS FOR CARDIAC TREATMENTS - Compositions for platelet rich plasma (PRP) are provided. Generally, these compositions comprise a higher concentration of platelets and white blood cells than whole blood. The concentrations of the platelets and/or the white blood cells may be two to eight times the respective concentrations in whole blood. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy. | 04-15-2010 |
20100092445 | Adoptive immune cells for tumor vaccines - Adoptive immune cells obtained by a method including (a) obtaining mammalian antigen-presenting associated cells; (b) culturing the resulting cells from step (a) in a culture liquid contained in a culture vessel coated with a sugar chain-containing polymer; and (c) detaching the cells from step (b) by shaking the culture vessel without treating the cells with an enzyme and without using a cell detaching tool. A method for treating a malignant tumor, type I diabetes, an atopic allergic disease or an infection, by administering the adoptive immune cells to a patient. A pharmaceutical composition for treating a malignant tumor, type I diabetes, an atopic allergic disease or an infection, including the adoptive immune cells and a pharmaceutically acceptable carrier. | 04-15-2010 |
20100104546 | MODULATORS OF ANTIGEN-DEPENDENT T CELL PROLIFERATION - The present invention relates to a method of inhibiting antigen-dependent proliferation of T-cells in a subject without substantially inhibiting mitogen-dependent proliferation of T-cells in the subject. The method includes administering to the subject an effective amount of a polyunsaturated fatty acid, or a salt or derivative of a polyunsaturated fatty acid. | 04-29-2010 |
20100111916 | Materials and Method of Modulating the Immune Response - Methods and materials to modulate the immune response to treat or prevent a disease or to prevent transplant rejection, including methods of making T helper-antigen presenting cells and/or T regulatory-antigen specific cells and methods of using these cells. The invention also relates to methods of making exosome-absorbed dendritic cells and the uses of these cells to modulate the immune response to treat or prevent a disease or to prevent transplant rejection. | 05-06-2010 |
20100129339 | NKT CELL-STIMULATING AGENT FOR ADMINISTRATION THROUGH UPPER RESPIRATORY TRACT MUCOUS MEMBRANE - The present invention provides an NKT cell stimulating agent containing antigen-presenting cells pulsed with an NKT cell ligand, to be administered submucosally in the upper airway. By submucosal administration in the upper airway, it is possible to stimulate NKT cells and stimulate immune reactions extremely efficiently with a small number of NKT cell ligand-pulsed antigen-presenting cells. By submucosal administration in the upper airway, NKT cells can be induced selectively in cervical lymph nodes. | 05-27-2010 |
20100129340 | METHODS AND MATERIALS FOR THE GENERATION OF REGULATORY T CELLS - Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25− T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed. | 05-27-2010 |
20100135974 | REDIRECTED, GENETICALLY-ENGINEERED T REGULATORY CELLS AND THEIR USE IN SUPPRESSION OF AUTOIMMUNE AND INFLAMMATORY DISEASE - A redirected Treg cell is endowed with specificity toward a selected target antigen or ligand. The cell contains a chimeric receptor polypeptide that is expressed in a single, continuous chain, with an extracellular recognition region displayed on the surface of the cell, a transmembrane region and an intracellular signaling region. The extracellular recognition region is specific for the selected target antigen or ligand. The intracellular signaling region includes a combination of T-cell signaling polypeptide moieties, which combination, upon binding of the extracellular recognition region to the selected target antigen or ligand, triggers activation of the redirected Treg cells to cause suppression of T-cell mediated immunity. Such redirected Treg cells may be used to suppress undesired activity of T effector cells thereby mediating an immune or inflammatory response. They are particularly useful in treating T effector cell-mediated diseases, such as inflammatory bowel disease, transplant rejection and GVH disease. | 06-03-2010 |
20100135975 | CD133 Epitopes - An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders. | 06-03-2010 |
20100166722 | T CELL THERAPIES - This invention provides a method of treating cancer or infection by administering T cells transfected with T cell receptors (TCRs) which in their soluble form have a half life for their interaction with their cognate peptide-MHC complex chosen to enhance the avidity of the T cells for target cells presenting that peptide MHC complex while maintaining the activation specificity of the T cells by that peptide-MHC complex. | 07-01-2010 |
20100172888 | HCV-REACTIVE T CELL RECEPTORS - Provided are cells expressing HCV epitope-reactive recombinant T cell receptors useful in the treatment and/or prevention of acute or chronic HCV and HCV-related conditions or malignancies. The invention further provides methods of preparing HCV epitope-reactive T cell receptors and methods of treatment using cells expressing HCV epitope-reactive recombinant T cell receptors. Polynucleotides, constructs and vectors encoding HCV epitope-reactive recombinant T cell receptors are also provided. | 07-08-2010 |
20100183575 | Compositions and Methods for Producing Adaptive Regulatory T Cells - The present invention relates to a method for producing adaptive regulatory T cells from effector T cells by contacting the effector T cells with retinoic acid. Adaptive regulatory T cells produced by this method are Foxp3+, home to the gut, and are refractory to reversion in vivo. As such, such cells find application in the treatment of autoimmune disease and facilitating transplantation tolerance. | 07-22-2010 |
20100189703 | NON-DESTRUCTIVE METHOD TO QUANTIFY AND ISOLATE ANTIGEN-SPECIFIC B CELLS AND USES THEREOF - The present invention relates to antigen-Ig Ab fusion molecules and methods of using same, wherein antigen-Ig Ab fusion molecules include an antigen fused to an immunoglobulin molecule, fragment or variant thereof and wherein the fusing of the immunoglobulin molecule to the antigen does not alter the specificity or tertiary structure of important epitopes of the antigen. This method allows the direct quantification and isolation of antigen-specific B cells by flow cytometry in essentially any species. | 07-29-2010 |
20100203027 | VIRAL VECTOR FOR GENE THERAPY - An objective of the present invention is to provide safe viral vectors for gene therapy that can be introduced by a simple technique and sufficiently express genes of interest in vivo. The present inventors demonstrated that anti-tumor effect can be produced when a heparin-binding cytokine such as granulocyte macrophage colony stimulating factor (GM-CSF) and a chemokine such as TARC or RANTES are expressed in vivo using a viral vector based on a negative-strand RNA virus. The present inventors also demonstrated that the protective effect of the vector is superior to that of conventional adenovirus vectors. Thus, the present invention relates to negative-strand RNA viral vectors comprising a cytokine gene and a chemokine gene. The viral vectors are suitable for treatment of cancers, in particular, metastatic cancers. The present invention also provides compositions comprising such viral vectors, and gene therapy methods using them. | 08-12-2010 |
20100209408 | Remodeling of Tissues and Organs - The invention provides methods of repairing damage to, or defects in, mammalian tissues or organs. In these methods, a particulate or non-particulate acellular matrix made from a tissue or organ other than the tissue or organ being repaired is placed in or on the organ or tissue that is being repaired. | 08-19-2010 |
20100209409 | METHOD FOR SUPPRESSING IMMUNE SYSTEM RESPONSE TO TRANSPLANTED TISSUE OR CELLS - Methods are provided for suppressing the immune system response in recipients of transplanted organs, tissues or cells. An extracorporeal quantity of blood from the intended transplant recipient is treated to induce monocytes contained in the blood to differentiate and form dendritic cells. The maturation of the dendritic cells is truncated at a stage where the dendritic cells can inactivate T cell clones which would otherwise generate an undesired immune system response. The immature dendritic cells can be directly administered to the transplant recipient, or the dendritic cells can be co-incubated with the bone marrow or stem cell preparation, prior to transplantation, in order to suppress or eliminate anti-recipient donor T cells contaminating the bone marrow or stem cell preparation. The methods can be used to suppress graft versus host disease in recipients of transplanted bone marrow or stem cells, or to suppress rejection of transplanted organs or tissue. | 08-19-2010 |
20100215628 | METHOD FOR PREPARING CELL POPULATIONS WITH ANTI-TUMOR IMMUNE RESPONSE ACTIVITY - The invention provides a method for preparing cell populations with anti-tumor immune response activity, which includes co-culturing tumor and mononuclear cell in a three-dimensional cell culture device, separating and amplifying the cell populations with anti-tumor immune response activity from the cultures. The present invention, at the same time, discloses the cell populations with anti-tumor immune response activity obtained by the method and the kit comprising the cell populations. | 08-26-2010 |
20100215629 | TREATMENT OF TUMORS USING T LYMPHOCYTE PREPARATIONS - The invention relates to the treatment of a tumor in a patient, by injecting T lymphocytes depleted of regulatory T lymphocytes, and expressing a molecule allowing their specific destruction, the patient receiving beforehand a non-myeloablative or myeloablative lymphopenic treatment. | 08-26-2010 |
20100226901 | GENETIC CONTROL OF MAMMALIAN CELLS WITH SYNTHETIC RNA REGULATORY SYSTEMS - The present application relates to nucleic acids that encode a RNA switch responsive to a ligand that can control the expression of a gene product that affects the cell fate determination of a mammalian cell are provided. In some embodiments, the system can be used to control the proliferation or activation of mammalian cells in response to a ligand that can be provided exogenously to the mammalian cell or can be produced by the mammalian cell. The system can be used to promote the growth or proliferation of human T cells in response to an exogenous ligand applied to the cells. In one embodiment, the system detects the ligand through a RNA aptamer that modulates expression of a gene product through activation or inactivation of a ribozyme that modulates expression of the gene product. | 09-09-2010 |
20100239547 | SYNTHETIC HLA BINDING PEPTIDE ANALOGUES AND USES THEREOF - The present invention is directed to a synthetic peptide comprising a sequence of amino acids containing at least a segment that is an analogue of a native peptide that specifically binds to HLA A0201 or HLA A0301 molecules on a cell characteristic of a pathophysiologic state in a mammal. The synthetic peptide may be derived form native peptides comprising a breakpoint region of the WT1 protein. | 09-23-2010 |
20100239548 | Isolation and Identification of T Cells - The present invention relates to improved autologous T cell vaccines and improved methods for their production. The invention is also directed to methods for treating autoimmune diseases such as multiple sclerosis or rheumatoid arthritis using autologous T cell vaccines. The invention further directed to the diagnosis of T associated diseases. | 09-23-2010 |
20100247502 | TUMOR/B-CELL HYBRID CELLS AND USES THEREOF - The present invention is directed to methods and compositions for slowing or inhibiting the growth of tumors and decreasing the size of existing tumors. The compositions include dendritic cells contacted with tumor/B-cell hybrid cells and various T-cells contacted with tumor/B-cell hybrid cells (TBH cells). The present invention further encompasses methods of generating such compositions and methods of use of such compositions. | 09-30-2010 |
20100254958 | Antigen-Specific T-Cell Preparations from Bone Marrow - A method for the generation of antigen-specific T-cell preparations for adoptive therapy is provided, comprising the steps of obtaining lymphoid cells from the bone marrow of a patient in a first step, expanding the lymphoid cells in cell culture medium ex-vivo in the presence of at least one of IL2 and IL7 and or more antigens, yielding a T-cell preparation, and isolating the T-cell preparation from the culture medium in an isolation step. T-cell preparations provided according to the inventive method, and the use of such T-cell preparations for the treatment of infectious disease and cancer is also provided. | 10-07-2010 |
20100260734 | METHOD OF STIMULATING PROSAPOSIN RECEPTOR ACTIVITY - A method for stimulating prosaposin receptor activity in a cell by transfecting the cell with a DNA or RNA molecule encoding prosaposin or a prosaposin receptor agonist. The DNA or RNA molecule is administered either in vivo or used to transfect neural cells or neural stem cells ex vivo followed by reintroduction of the cells into an individual. | 10-14-2010 |
20100266561 | Recovery of Tissue Function Following Administration of B Cells to Injured Tissue - The present invention relates generally to systems and methods of enhancing recovery of function of injured tissue through administration of a composition comprising a relatively pure populations of B lymphocyte cells in a pharmaceutically acceptable carrier to the injured tissue. Kits are provided to aid in purification of B cells from heterogeneous mixtures of cells and administration of B cells to injured tissue. | 10-21-2010 |
20100266562 | SELECTIVE CYTOPHERESIS DEVICES AND RELATED METHODS THEREOF - The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action. | 10-21-2010 |
20100266563 | SELECTIVE CYTOPHERESIS DEVICES AND RELATED METHODS THEREOF - The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action. | 10-21-2010 |
20100272700 | DENDRITIC CELL PRECURSORS - A method of generating a population of dendritic cell (DC) precursors includes obtaining a population of progenitor cells from a subject and culturing the progenitor cells in a culture medium. The culture medium can include Flt3 ligand and interleukin-6 and be free of granulocyte-macrophage colony-stimulating factor. | 10-28-2010 |
20100291054 | NOVEL REGULATORY T CELLS AND USES THEREOF - The invention provides isolated regulatory T cells and methods of obtaining regulatory T cells. The invention also provides methods for inhibiting an antigen-specific immune response (e.g., graft rejection, an autoimmune disorder, graft versus host disease, a response to a tumor cell, a response to an infection, and a response to an allergen) in a subject requiring administering an isolated regulatory T cell to the subject. The invention further provides methods for treating or modulating an antigen-specific immune response in a subject requiring administering a regulatory T cell to the subject. | 11-18-2010 |
20100297093 | MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS - The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with one or more amino acid substitutions in the CDR2 and/or CDR3 regions of the alpha and/or beta chains of the TCR, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4 | 11-25-2010 |
20100297094 | THERAPY OR PREVENTION OF DISEASES WITH CELLS OR CELL SUPERNATANT - Methods and compositions for the treatment or prevention of diseases or disorders including media conditioned by mesenchymal stem cells and BCL2A1 are provided. Methods for the production of therapeutic or preventative compositions contacted with BCL2A1 are also provided. | 11-25-2010 |
20100303779 | Non-Conventional NKT Cells for Use in Cancer Therapy - The invention relates to the use of CD Id-independent NKT cells, for the preparation of a pharmaceutical composition for treating a tumor in a patient. Said CD1d-independent NKT cells may be obtained by (a) culturing a population of T cells under conditions which suppress TGFβ signalling pathway, and (b) selecting the cells which exhibit at least one NK marker. | 12-02-2010 |
20100303780 | COMPOSITIONS FOR TREATING AN INTESTINAL INFLAMMATORY CONDITION - Compositions comprising human Tr1 cells directed to a food antigen from common human diet and methods for treating an intestinal inflammatory condition. | 12-02-2010 |
20100310533 | METHODS OF USING IL-21 FOR ADOPTIVE IMMUNOTHERAPY AND IDENTIFICATION OF TUMOR ANTIGENS - Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of IL-21 compositions and antigen presenting cells (APCs), the resulting T cell population has an enhanced antigen-specificity, and can be reintroduced into the patient. Methods are also disclosed for identifying tumor antigens by culturing T cell populations exposed to IL-21 compositions and APCs in the presence of tumor material. | 12-09-2010 |
20100310534 | T CELL SUBPOPULATIONS CAPABLE OF TREATING CANCER - A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8 | 12-09-2010 |
20100310535 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND - An object of the present invention is to expand CD34 | 12-09-2010 |
20100310536 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND - An object of the present invention is to expand CD34 | 12-09-2010 |
20100310537 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND - An object of the present invention is to expand CD34 | 12-09-2010 |
20100322910 | METHODS OF OBTAINING ANTIGEN-SPECIFIC T CELL POPULATIONS - The invention provides a method of obtaining a population of antigen-specific T cells from peripheral blood of a host. An embodiment of the method of the invention comprises (i) dividing PBMCs from peripheral blood of a host into more than one sub-population; (ii) contacting the PBMCs with an antigen and IL-2; (iii) obtaining a sample of PBMCs from each sub-population; (iv) identifying an antigen-reactive sub-population by determining by high throughput quantitative PCR the expression of a factor produced by the PBMCs of each sample; (v) dividing the antigen-reactive sub-population into microcultures; (vi) identifying the antigen-reactive microculture; and (vii) expanding the microculture, thereby obtaining a population of T cells specific for the antigen. The invention also provides a population of T cells obtained by the inventive method, a pharmaceutical composition comprising the same, and a method of treating a disease in a host using the pharmaceutical composition. Related isolating and screening methods are further provided. | 12-23-2010 |
20100330056 | ENHANCED GENERATION OF CYTOTOXIC T-LYMPHOCYTES BY IL-21 MEDIATED FOXP3 SUPPRESSION - A method of carrying out adoptive immunotherapy by administering a subject an antigen-specific cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount is described. In the method, the CTL preparation is preferably administered as a preparation of an in vitro antigen-stimulated and expanded primate CTL population, the CTL population: (i) depleted of FoxP3+ T lymphocytes prior to antigen stimulation; (ii) antigen-stimulated in vitro in the presence of interleukin-21; or (iii) both depleted of FoxP3+ T lymphocytes prior to antigen stimulation and then antigen-stimulated in vitro in the presence of interleukin-21. Methods of preparing such compositions, and compositions useful for carrying out the adoptive immunotherapy, are also described. | 12-30-2010 |
20100330057 | METHOD OF EVALUATING HUMAN DENTRITIC CELLS AND HUMAN CELL IMMUNOTHERAPEUTIC AGENT - The invention provides a method of evaluating the antigen presentation potential of human dendritic cells by administering α-galactosylceramide-pulsed human dendritic cells to a non-human mammal; collecting a sample containing NKT cells from the non-human mammal; and detecting the activation of NKT cells present in the sample. The invention further provides an agent for human NKT cell immunotherapy, which contains human dendritic cells that have been assessed by the aforementioned method as those possessing an antigen presentation potential for NKT cells. | 12-30-2010 |
20110002903 | IMMUNOGENIC CONTROL OF TUMOURS AND TUMOUR CELLS - The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a tumour-associated antigen and a redox motif such as C—(X)2-[CST] or [CST]-(X)2-C in the treatment of a tumour or in the treatment or prevention of a tumour relapse, and in the manufacture of medicaments therefore. | 01-06-2011 |
20110008304 | USE OF CELLS TO FACILITATE TARGETED DELIVERY OF NANOPARTICLE THERAPIES - The present invention is related to the use of cells, such as stem cells or immune system cells, to deliver nanogels comprising an active agent to a desired site in the body. The present invention utilizes cells as a delivery system for active agents that are difficult to deliver, such as active agents with poor solubility, that degrade easily, or that are toxic to the body. The nanogels are preferably non-toxic and can optionally include a lytic agent to program apoptosis of the cell to deliver the nanogel and active agent to a desired sire within the body. | 01-13-2011 |
20110014169 | HIGH AFFINITY NY-ESO T CELL RECEPTORS - The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a K | 01-20-2011 |
20110020308 | EXPRESSION OF TRANSGENIC T CELL RECEPTORS IN LAK-T CELLS - The present invention is directed to LAK-T cells, which have been transformed by a transgenic T cell receptor (tg-TCR). The invention is further directed to a method of generating those transgenic T cells, a pharmaceutical composition comprising said cells and the use of the LAK-T cells or of the pharmaceutical composition in the adoptive cell therapy and for treating hematological malignancies or solid tumors or acute or chronic infections or autoimmune diseases. | 01-27-2011 |
20110020309 | EX-VIVO PRIMING FOR GENERATING CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR NON-TUMOR ANTIGENS TO TREAT AUTOIMMUNE AND ALLERGICE DISEASE - Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo. | 01-27-2011 |
20110020310 | ROOT CANAL FILLER AND DENTAL TISSUE REGENERATION METHOD - Provided is a novel and creative dental tissue regeneration method for regenerating dental tissue after pulpectomy or the enlargement and cleaning of an infected root canal. After pulpectomy or the enlargement and cleaning of an infected root canal, a root canal filler ( | 01-27-2011 |
20110027244 | Compositions and methods of preparing alloreactive cytotoxic T cells - Provided herein are compositions and methods of preparing therapeutic cytotoxic T cells. In certain embodiments, such T cells are generated through activation of donor cells by patient stimulator cells. | 02-03-2011 |
20110027245 | Pairing processes for preparing alloreactive cytotoxic T cells - Provided in certain embodiments are methods for pairing patient cells and donor cells to prepare cytotoxic T cells. Such cytotoxic T cells could be administered to the patient for treating certain disorders, such as a cancer (for example, brain cancer). | 02-03-2011 |
20110033434 | CULTURED THREE-DIMENSIONAL TISSUES AND USES THEREOF - The present disclosure provides compositions of three dimensional tissue that can be administered into tissues and organs using minimally invasive methods. The three dimensional tissues elaborate a repertoire of growth factors that facilitate repair or regeneration of damaged tissues and organs. | 02-10-2011 |
20110033435 | Composition of activated CD4 cells - The composition of activated CD4 cells is derived from a healthy human donor. The composition from the healthy human donor is suspended in an infusion media and packaged in a vehicle for administration to a subject to treat disease. | 02-10-2011 |
20110038842 | High affinity ny-eso t cell receptor - The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a K | 02-17-2011 |
20110038843 | Tumor Growth Inhibition Via Conditioning of Tumor Microenvironment - Disclosed herein are methods and materials for inhibiting tumor growth by administering viral vectors to tumor cells. Particularly exemplified herein are methods of inhibiting tumor growth of colon tumors by delivering 15-PGDH to tumor environment. Antigen presenting cells may be coadministered with 15-PGDH. | 02-17-2011 |
20110038844 | COMPOSITIONS FOR TREATING AN ARTHRITIC CONDITION - The present invention relates to compositions comprising human Tr1 cells directed to a joint-associated antigen and methods for treating an arthritic condition. | 02-17-2011 |
20110044962 | NOTCH INDUCED NATURAL KILLER CELL GENERATION AND THERAPEUTIC USES - A method of preparing differentiated NK cells by ex vivo expansion includes the steps of; (1) isolating a plurality of CD34 | 02-24-2011 |
20110052554 | METHODS FOR OFF-THE- SHELF TUMOR IMMUNOTHERAPY USING ALLOGENEIC T-CELL PRECURSORS - The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy. | 03-03-2011 |
20110059059 | Methods for Treating Ischemic Tissue - Compositions and methods for treating ischemic tissue are provided herein. | 03-10-2011 |
20110064709 | USE OF ECDI-FIXED CELL TOLERANCE AS A METHOD FOR PREVENTING ALLOGRAFT REJECTION - The present invention provides methods, systems, and compositions for inducing donor-specific tolerance. In particular, the present invention provides methods of administering ECDI-treated cells before, during, and/or after administration of donor transplant cells or a donor allograft in order to induce tolerance for the cells and/or allograft in a recipient. | 03-17-2011 |
20110076258 | METHODS OF MODULATING T CELL- DEPENDENT IMMUNE RESPONSES - The present invention provides methods and compositions for modulating at least one T cell-dependent immune response using an inhibitor of ATP-mediated T cell activation, such as oxidized ATP, for therapeutic and research purposes. | 03-31-2011 |
20110091433 | TREATMENT USING REPROGRAMMED MATURE ADULT CELLS - A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient. In certain embodiments, the method comprises obtaining committed cells from the patient, transdifferentiating the committed cells to obtain transdifferentiated target cells, and administering the transdifferentiated target cells to the patient. The retrodifferentiated or transdifferentiated target cells repair or replenish tissue or cells in the patient. | 04-21-2011 |
20110091434 | AUGMENTATION OF CELL THERAPY EFFICACY INCLUDING TREATMENT WITH ALPHA 1-3 FUCOSYLTRANSFERASE - Disclosed are methods, compositions of matter, and kits useful for augmentation of homing and engraftment of stem, progenitor and mature cells through modification of cellular membrane properties following ex vivo treatment. The methods, compositions, and cells may be used for the treatment of a wide variety of disorders in which augmentation of cell trafficking, homing and engraftment is desired. | 04-21-2011 |
20110097312 | ANTI-CANCER VACCINES - The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as immunogenic compositions for treating and/or preventing breast cancer in an individual. In specific aspects, PR1 peptide or a derivative thereof, or a myeloperoxidase peptide, or a cyclin E1 or E2 peptide is provided in methods and compositions for breast cancer treatment and/or prevention. Such peptides can be used to elicit specific CTLs that preferentially attack breast cancer based on overexpression of the target protein cells. | 04-28-2011 |
20110097313 | Method for the Identification and Separation of Non-regulatory T-cells from a Mixture of Regulatory T-cells - The present invention relates to a method of identifying and separating non-regulatory T-cells (conventional T-cells) from a mixture comprising regulatory T-cells by using of the CD154 molecule (CD40 ligand) through depletion of CD154+ T-cells from the mixture or in combination with additional positive selection of Treg using markers that are specific for regulatory T-cells, such as for example, CD25, GITR, CTLA4 or markers which are specific for activated regulatory T-cells, such as, for example, CD137, “latent TGF-beta (LAP)”, GARP (LRRC32), CD121a/b, thereby generating a cell composition of activated Treg cells. The invention relates also to a kit comprising an antibody for detecting CD154 and at least one additional antibody for detecting markers for activated or non-activated regulatory T-cells. The antibodies can be coupled to a fluorescent dye or magnetic microparticles. | 04-28-2011 |
20110097314 | METHOD FOR PRODUCING A COMPOSITION FOR PROMOTING SURVIVAL OF TRANSPLANTED HEMATOPOIETIC STEM CELL - HLA matched activated lymphocytes in mononuclear cells separated from peripheral blood or umbilical cord blood are proliferated and activated. After separating and collecting, the HLA matched activated lymphocytes are employed as the main component of a composition for promoting survival of transplanted hematopoietic stem cells. The obtained composition is widely usable in, for instance, prevention of survival failure of transplanted hematopoietic stem cells and therapy for promoting the survival thereof. Although the dose of the composition varies depending on the age, conditions, etc. of a patient, a humanized antibody is administered in a dose of from 0.2 to 20 ml/kg/day to mammals including humans. The composition is administered by intravenous injection either once a day (single administration or continuous administration) or intermittently once to 3 times in a week or once in 2 or 3 weeks. | 04-28-2011 |
20110104136 | Natural Killer p30 (NKp30) Dysfunction and the Biological Applications Thereof - The present invention relates to a method of assessing a favourable or, on the contrary, an unfavourable prognosis of a cancer in the subject, which method comprises detecting the presence of a mutated Natural Cytotoxicity-triggering Receptor 3 (NCR3) nucleic acid, an abnormal relative amount of at least one particular Natural Killer p30 (NKp30) RNA transcript isoform, and/or an abnormal Natural Killer p30 (NKp30) expression or activity of at least one particular NKp30 protein isoform in a sample from the subject, the presence of said mutated NCR3 nucleic acid, abnormal relative amount of at least one particular NKp30 RNA transcript isoform, or abnormal expression or activity of at least one particular NKp30 protein isoform being indicative of the prognosis of said cancer in the subject. | 05-05-2011 |
20110110908 | TREATMENT OF DISEASE CONDITIONS VIA ADMINISTRATION OF DNA REPAIR ENZYME - The present invention is directed to compositions and methods of preserving viability of islets of Langerhans for transplantation, and treating various diseases and other abnormal or pathological conditions, including inflammatory bowel disease, ischemic heart disease, acute lung injury, acute respiratory distress syndrome and radiation-induced brain injury, with DNA repair enzymes that are directed to the mitochondria. | 05-12-2011 |
20110110909 | HUMAN FACILITATING CELLS - The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs. | 05-12-2011 |
20110117069 | METHOD FOR ACTIVATING REGULATORY T-CELLS - The invention relates to a method for activating regulatory t-cells (Treg-cells) of the human or animal body, comprising a step of bringing into contact the regulatory t-cells (Treg-cells) in a suitable liquid medium with one or a plurality of inhibitors of alanyl-amino peptidase (amino peptidase N; APN) and/or with one or a plurality of inhibitors of peptidases with the same substrate specificity to induce a suppressive effect of the regulatory t-cells (Treg-cells). | 05-19-2011 |
20110123502 | METHOD FOR OBTAINING TREG-CELLS - A method for generating a population of functional regulatory T cells (T | 05-26-2011 |
20110135617 | Pairing processes for preparing reactive cytotoxic T cells - Provided in certain embodiments are methods for pairing patient cells and donor cells to prepare cytotoxic T cells, either in vitro or, when their formation is induced in a subject, in vivo. Such cytotoxic T cells could be administered to the patient for treating certain disorders, such as a cancer (for example, brain cancer). | 06-09-2011 |
20110142812 | SUPPRESSIVE MACROPHAGES, C-REACTIVE PROTEIN AND THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIC PURPURA - The present invention relates to the use of suppressive macrophage or dendritic cells (activated with C-reactive protein or CRP-related compounds), for the treatment of various disease states and conditions associated with immune thrombocytopenic purpura (ITP) and/or systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with systemic lupus erythematosus or ITP will have an outbreak is an additional aspect of the present invention. In the case of ITP, methods of the present invention are used to increase platelet counts in the treated patient. In addition, in the case of ITP, the present invention relates to the use of CRP or a CRP-related compound in the absence of suppressive macrophages for the treatment of ITP. | 06-16-2011 |
20110142813 | Use Of Anti-Cancer Cell Composition For Treatment Of Head And Neck Cancer, Which Is Intended To Be Administered To Nutrient Artery Of Tumor - To provide a method of efficiently delivering cells having an anti-tumor activity to tumor tissues to evoke a stronger anti-tumor reaction, and a method of providing a more effective tumor regression effect, both in a cellular immunotherapy for cancer utilizing cells having an anti-tumor activity or antigen presenting cells for activating cells capable of exhibiting an anti-tumor activity. Provided are: a method of treating head and neck cancer, comprising administering an anti-cancer cell composition containing NKT cells activated in vitro with an NKT cell ligand into the tumor-feeding artery, and administering an NKT cell-stimulating agent containing antigen presenting cells treated with an NKT cell ligand through the upper respiratory tract mucous membrane; a use, in anti-cancer treatment of head and neck region, of the anti-cancer cell composition and the NKT cell-stimulating agent; a kit comprising the anti-cancer cell composition and the NKT cell-stimulating agent; and the anti-cancer cell composition. | 06-16-2011 |
20110142814 | Methods for Using Protein Kinase C-Theta Inhibitors in Adoptive Immunotherapy - The present invention provides methods for reducing tumor necrosis factor activation of regulatory T cells (Tregs), restoring the activity of defective Tregs, and enhancing the function of Tregs using Protein Kinase C theta (PKC-θ) inhibitors. The enhancement in Treg function is of use in facilitating adoptive immunotherapy in the treatment of immunological disorders. | 06-16-2011 |
20110182870 | GENERATION OF CTL LINES WITH SPECIFICITY AGAINST MULTIPLE TUMOR ANTIGENS OR MULTIPLE VIRUSES - The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane. | 07-28-2011 |
20110189150 | TANGENTIAL FLOW FILTRATION DEVICES AND METHODS FOR LEUKOCYTE ENRICHMENT - The present invention provides tangential flow filtration devices and methods for enriching a heterogenous mixture of blood constituents for leukocytes by removal of non-leukocyte blood constituents. In one particular embodiment the device can provide a composition enriched in monocytes. | 08-04-2011 |
20110212071 | ANTI THIRD PARTY CENTRAL MEMORY T CELLS, METHODS OF PRODUCING SAME AND USE OF SAME IN TRANSPLANTATION AND DISEASE TREATMENT - An isolated population of cells comprising non-GVHD inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype is provided. The cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation. Methods of generating same, use of same and methods of treatment are also provided. | 09-01-2011 |
20110223145 | IMMUNOSUPPRESSIVE BLOOD CELLS AND METHODS OF PRODUCING THE SAME - The present invention refers to a method of producing immunosuppressive blood cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease. | 09-15-2011 |
20110223146 | METHODS FOR PREPARATION AND USE OF MARROW INFILTRATNG LYMPHOCTYES (MILS) - The invention provides compositions comprising activated marrow infiltrating lymphocytes, methods of generating populations of marrow infiltrating lymphocytes, uses of the marrow infiltrating lymphocytes of the invention, and a culture device for use in cell culture, for example for use in generating populations of activated marrow infiltrating lymphocytes. In certain embodiments, the marrow infiltrating lymphocytes can be used as a cancer therapeutic. | 09-15-2011 |
20110229448 | METHOD FOR IDENTIFYING ANTIGEN-SPECIFIC REGULATORY T CELLS - A method of identifying an antigen-specific regulatory T cell (Treg) from a subject is discussed wherein the method comprises quantitatively or qualitatively detecting co-expression of each of cell markers CD4, CD25 and CD134, or alternatively, N each of cell markers CD8, CD25 and CD137, as well as one or more cell markers selected from the group of Treg cell markers consisting of CD39, CD73, CD127, CTLA-4 and Foxp3 on a cell in a suitable lymphocyte-containing sample from the subject in response to exposure to a target antigen. Also discussed are methods of isolating and expanding the identified antigen-specific Treg population, which may permit antigen-specific Treg cell therapy. | 09-22-2011 |
20110236362 | NKT CELL-DERIVED iPS CELLS AND NKT CELLS DERIVED THEREFROM - Provided are an iPS cell derived from a somatic cell such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, NKT cells differentiated from the iPS cell, a method of creating the same, and an immune cell therapy agent prepared using cells differentiated from the iPS cell. Also provided are an iPS cell having TCRα rearranged to NKT-TCR (NKT-iPS cell), obtained by contacting a somatic cell, such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, with nuclear reprogramming factors, isolated NKT cells obtained by differentiating the iPS cell ex vivo (iPS-NKT cell), a method of generating CD4/CD8-double positive NKT cells (DP-NKT cells) and mature NKT cells from NKT-iPS cells by altering the combination of feeder cells and/or cytokines, a method of expanding the iPS-NKT cells, and an NKT cell cytotherapy agent comprising NKT cells activated with α-galactosyl ceramide (α-GalCer), or iPS-NKT cells, and α-GalCer in combination. | 09-29-2011 |
20110236363 | SYSTEM AND METHOD FOR PRODUCING T CELLS - Disclosed herein is a system and method for producing T cells from stem cell populations. Specifically exemplified herein is a culture system and method that produces CD4 cells and/or T cell subtypes from a CD4 lineage using a sample of hematopoietic stem cells. Adult hematopoietic precursor/stem cells (HPC) are progenitors to all lineages of immune cells. There has been limited success in generating functional CD4 T cells with this convenient culture system. Also disclosed herein is a novel stromal cell line expressing DL1, interleukin-7 (IL-7), and FMS-like tyrosine kinase 3 ligand (Flt3-L). This improved culture system can greatly facilitate the study of late T cell development and enables immunotherapeutic applications. | 09-29-2011 |
20110250190 | PHARMACEUTICAL PREPARATION - The present invention relates to a pharmaceutical preparation for treating an inflammatory condition, preferably a condition associated with ischemia comprising: a) a physiological solution comprising peripheral blood mononuclear cells (PBM-Cs) or a subset thereof, or b) a supernatant of the solution a), wherein the solution a) is obtainable by cultivating PBMCs or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h. | 10-13-2011 |
20110262413 | METHODS OF REDUCING EXTRAVASATION OF INFLAMMATORY CELLS - A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease. | 10-27-2011 |
20110262414 | HIGH AFFINITY NY-ESO T CELL RECEPTORS - The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a K | 10-27-2011 |
20110268716 | METHODS FOR THE ENRICHMENT OF VIABLE FOXP3+ CELLS AND USES THEREOF - The present invention is directed to methods of identifying and enriching for viable Foxp3 | 11-03-2011 |
20110274674 | ISCHEMIC TISSUE CELL THERAPY - The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina. | 11-10-2011 |
20110274675 | Therapeutically Useful Molecules - A T cell receptor molecule (TCR) containing an alpha chain portion and a beta chain portion wherein the alpha chain portion contains three complementarily determining regions (CDRs): CDR1α: SSYSPS CDR2α: YTSAATL CDR3α: VVSPFSGGGADGLT or comprising or consisting of SPPSGGGADGLT and the beta chain portion contains three complementarity determining regions (CDRs): CDR1β: DFQATT CDR2β: SNEGSKA CDR3β: comprising SARDGGEG or comprising or consisting of RDGGEGSETQY, or wherein up to three amino acid residues in one or more CDRs are replaced by another amino acid residue. The invention also includes polynucleotides encoding the TCR molecules, and host cells containing the said polynucleotides. Patient derived T cells may have the polynucleotides encoding the TCR molecules introduced therein, and the engineered T cells may be introduced into the patient in order to combat a WT1-expressing malignancy. | 11-10-2011 |
20110280849 | TUMOR SUPPRESSION USING HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS AND IMMUNOMODULATORY COMPOUNDS - Provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising contacting the tumor cells, or administering to the individual, placental perfusate, placental perfusate cells, or natural killer cells, e.g., placenta-derived intermediate natural killer cells, with an immunomodulatory compound or thalidomide. | 11-17-2011 |
20110300119 | METHODS OF ENRICHING AND USING REGULATORY T CELLS - Disclosed are methods of isolating and using a population of FOXP3 | 12-08-2011 |
20110305680 | Composition Containing Osteopontin for Differentiating Natural Killer Cell as an Active Ingredient and a Method of Differentiation Using Thereof - The present invention relates to a composition for differentiating natural killer cells comprising osteopontin (OPN) as an active ingredient and a method for differentiation using the same. More precisely, osteopontin of the present invention accelerates differentiation of natural killer cells from hematopoietic stem cells and increases cytotoxic activity of natural killer cells, so that it can be effectively used as a composition for differentiating natural killer cells. OPN of the present invention regulates differentiation of natural killer cells capable of killing cancer cells, so that it can be effectively used for the treatment of cancer. | 12-15-2011 |
20120009166 | Isolated monocyte populations and related therapeutic applications - The invention provides methods of using isolated monocyte populations to treat subjects suffering from various ocular vascular disease or ocular degenerative disorders. The present invention also provides novel methods for isolating substantially pure monocyte populations. The methods involve extracting a blood sample or a bone marrow sample from a subject, debulking red blood cells from the sample, and then separating remaining red blood cells and other cell types in the sample from monocytes. Instead of using any selection or labeling agents, the red blood cells and other cell types are separated from monocytes based on their size, granularity or density. The isolated monocytes can be further activated in vitro or ex vivo prior to being administered to a subject. Isolated cell populations containing substantially pure CD14 | 01-12-2012 |
20120027739 | T CELL RECEPTORS - A T cell receptor (TCR) having the property of binding to EVDPIGHLY HLA-A1 complex and comprising a specified wild type TCR which has specific mutations in the TCR alpha variable domain and/or the TCR beta variable domain to increase affinity. Such TCRs are useful for adoptive therapy. | 02-02-2012 |
20120045423 | Cells expressing TH1 characteristics and cytolytic properties - A novel cell type has been generated that has both Th1 characteristics and cytolytic activity. These Th1/killer cells are CD4+ cells purified from peripheral blood and manipulated to have Th1 characteristics such as production of IFN-gamma combined with cytolytic activity similar to cytotoxic T-cells (CTL). The CTL activity is targeted toward diseased cells, not normal cells. The cytolytic activity of the Th1/killer cells is mediated by Granzyme B-Perforin mechanism and results in apoptotic death of diseased cells. Methods of producing and using these Th1/killer cells include isolating CD4+ cells from peripheral blood, activating the CD4+ T-cells to form Th1/killer cells and administering these Th1/killer cells with the cytolytic activity to a patient wherein the Th1/killer cells are allogeneic to the patient. | 02-23-2012 |
20120058096 | COMPOSITIONS AND METHODS FOR GENERATING INTERLEUKIN-35-INDUCED REGULATORY T CELLS - Compositions and methods are provided for generating T cells having a regulatory phenotype from conventional T (T | 03-08-2012 |
20120093792 | IMMUNOTHERAPY FOR PANCREATIC CANCER - The present invention provides an immunotherapeutic agent and immunotherapy allowing the extension of the survival time of patients with pancreatic cancer. The immunotherapy of the present invention is characterized by comprising the steps of culturing peripheral blood lymphocytes of a patient with pancreatic cancer by stimulating the lymphocytes with an anti-CD3 antibody and an anti-CD52 antibody, thereby to obtain an immunotherapeutic agent, and administering at least four infusions of the resultant immunotherapeutic agent to the same patient, wherein each of the infusions of the immunotherapeutic agent comprises at least 15×10 | 04-19-2012 |
20120107292 | METHOD FOR THE SIMULTANEOUS INDUCTION OF CTL AND gamma-delta T CELL - Disclosed are: a method for culture of disease antigen specific CTLs and γδT cells in one culture step conveniently and efficiently; and a pharmaceutical agent and a therapeutic/prophylactic method both of which use a cell produced by the method. Blood is collected and peripheral blood mononuclear cells are separated from the blood. Aminobisphosphonate and a disease antigen are added to the peripheral blood mononuclear cells at the beginning of culture, and the cell culture is carried out for a predetermined period to proliferate/induce disease antigen specific CTLs and γδT cells simultaneously until the numbers of the cells reach values that are effective for the treatment of a disease. The CTLs and the γδT cells thus produced are used for the treatment. | 05-03-2012 |
20120107293 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - A method of treating cancer comprises: (a) providing allogenic or autologous white blood cells from a suitable donor; and then (b) administering the white blood cells to the subject in an amount effective to treat the cancer. Preferably the white blood cells comprise innate immune cells. Preferably the white blood cells comprise less than 10% by number of cytotoxic T lymphocytes. Preferably the white blood cells, or more particularly the innate immune cells, are preselected in vitro to kill cancer cells in vitro (for example, by collecting white blood cells from the patient and determining that the white blood cells kill cancer cells in vitro before and thereby pre-selecting the donor, before collecting a subsequent population of cells from the donor for administration). | 05-03-2012 |
20120107294 | COMPOSITION FOR IN VIVO TRANSPLANTATION FOR TREATMENT OF HUMAN CERVICAL CANCER COMPRISING MONONUCLEAR CELLS DERIVED FROM UMBLICAL CORD BLOOD - Provided is a composition for in vivo transplantation for the treatment of human cervical cancer, comprising mononuclear cells derived from umbilical cord blood and a pharmaceutically acceptable carrier. When the umbilical cord blood-derived mononuclear cells are transplanted in vivo, cervical cancer can be effectively treated. In particular, the mononuclear cells derived from the umbilical cord blood retain high differentiation and proliferation abilities and exhibit very low graft-versus-host (GVH) reactions which are side effects caused by transplantation, and thus, can be transplanted to many patients. | 05-03-2012 |
20120114623 | ANTIGEN-SPECIFIC LONG-TERM MEMORY T-CELLS - The present invention provides compositions, methods, and systems for generating antigen-specific long-term memory T-cells using mTOR pathway inhibitors. The present invention provides compositions, systems, and methods for administering antigen-specific long-term memory T-cells to a subject (e.g., to a subject with cancer in adoptive transfer type of procedures). | 05-10-2012 |
20120128646 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASE - The present invention is related to the development and treatment of autoimmune disease. Autoimmune diseases can result from tissue damage caused by the activation of autoreactive T cells by autoantigens. For example, peptide fragments of naturally occurring proteins (i.e., for example, chromogranin A) may activate autoreactive T cells that result in the destruction of pancreatic β islet cells, possibly by the release of inflammatory cytokines (i.e., for example, interferon-γ). One naturally occurring biologically active chromogranin A peptide fragment, WE14, may comprise a diabetogenic autoantigen. Truncation and extension analysis of WE14 indicates that the stimulating binding register of WE14 occupies only half of the mouse IA | 05-24-2012 |
20120148552 | METHOD AND COMPOSITIONS FOR ENHANCED ANTI-TUMOR EFFECTOR FUNCTIONING OF T CELLS - Integration of costimulatory signaling domains within a tumor targeting chimeric antigen receptor (CAR), such as the IL13Rα2 specific IL13-zetakine (IL13ζ), enhances T cell-mediated responses against tumors even in the absence of expressed ligands for costimulatory receptors. | 06-14-2012 |
20120148553 | METHODS OF GENERATING NATURAL KILLER CELLS - Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection. | 06-14-2012 |
20120177621 | Enhancement of Allogeneic Hematopoietic Stem Cell Transplantation - Methods and compositions are provided to augment the conversion of mixed hematopoietic cell chimerism to complete donor cell chimerism following allogeneic hematopoietic cell transplantation (HCT), where such transplantation may be utilized for treatment of cancer such as leukemia and lymphoma or for other conditions requiring reconstitution of the hematopoietic system, e.g. treatment of anemias, thalassemias, autoimmune conditions, and the like. The present invention improves on conventional DLI by utilizing a composition of substantially purified donor memory CD8 | 07-12-2012 |
20120183518 | ASSAY FOR DETERMINING HEALTH OF CD8+ T CELLS - A method of determining if a subject's CD8+ T-cells functionally recognize an HLA-E/Hsp60sp target structure comprising a) contacting a sample of the subject's CD8+ T-cells with a HLA-E+ cell loaded with Hsp60sp, b) quantifying proliferation of the contacted HLA-E+ cell, c) contacting a sample of the subject's CD8+ T-cells with a HLA-E+ cell which is loaded with a peptide which does not bind to HLA-E, d) quantifying proliferation of the HLA-E+ cell loaded with the peptide which does not bind to HLA-E following contact with the subject's CD8+ T-cells, e) comparing the proliferation quantified in step d) with the proliferation quantified in step b) | 07-19-2012 |
20120201799 | DEVICES, SYSTEMS AND METHODS FOR CELL MODIFICATION - A method of modifying cells includes removing fluid including cells from a patient, contacting the removed fluid from the patient with at least one surface upon which at least one agent to interact at least one cell receptor is immobilized to modify cells in the fluid, and returning the fluid to the patient. The agent can, for example, be immobilized via covalent bonding or ionic bonding to the at least one surface. The fluid can, for example, be blood or a blood fraction. The agent can, for example, be an agonist, an antagonist or an inverse agonist. | 08-09-2012 |
20120207727 | Regulatory T Cells and Their Use in Immunotherapy and Suppression of Autoimmune Responses - Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4 | 08-16-2012 |
20120213754 | Method of Preconditioning of Cell Suspensions - An apparatus for the preparation of cells for implantation into a living body is disclosed. The apparatus comprises a vessel substantially impermeable to gaseous oxygen; and fluid within said vessel, the fluid having a maximal dissolved oxygen capacity substantially equivalent to normal saline yet having a hypoxic oxygen concentration between about 0% to about 5% of said maximal dissolved oxygen capacity. The bag oxygen concentration level remains low when the apparatus is stored at 22°-25° C. in normal atmospheric conditions for a period of at least 30 days. The present invention simplifies the process of achieving donor cell hypoxic preconditioning for cell implantation, and may be used to bathe said cells to be transplanted for a sufficient time to activate the hypoxic metabolic pathway. | 08-23-2012 |
20120225043 | Enhancement of Immune Responses By 4-1BB-Binding Agents - This invention features methods of enhancing immune responses in mammalian subjects and in vitro methods of enhancing the response of a T cell. Also embodied by the invention are methods of receiving and preventing the induction of energy in T cells. | 09-06-2012 |
20120230966 | TISSUE TRANSPLANT COMPOSITIONS AND METHODS FOR USE - Provided are transplants and methods for augmenting formation and restoration of organ and tissue, for example, bone formation, by administering autologous or allogeneic human embryonic-like adult stem cells (ELA cells). Also provided is a method for augmenting formation of tissues and organs by administering a transplant having ELA stem cells or combination of ELA stem cells. | 09-13-2012 |
20120244133 | METHODS OF GROWING TUMOR INFILTRATING LYMPHOCYTES IN GAS-PERMEABLE CONTAINERS - An embodiment of the invention provides a method of promoting regression of cancer in a mammal comprising obtaining a tumor tissue sample from the mammal; culturing the tumor tissue sample in a first gas permeable container containing cell medium therein; obtaining tumor infiltrating lymphocytes (TIL) from the tumor tissue sample; expanding the number of TIL in a second gas permeable container containing cell medium therein using irradiated allogeneic feeder cells and/or irradiated autologous feeder cells; and administering the expanded number of TIL to the mammal. Methods of obtaining an expanded number of TIL from a mammal for adoptive cell immunotherapy are also provided. | 09-27-2012 |
20120251513 | Antigen Specific Tolerogenic Antigen Presenting Cells and Related Uses Compositions, Methods and Systems - The present disclosure relates to antigen specific tolerogenic antigen presenting cells presenting antigenic portions of an autoantigen and to related compositions, methods and systems. | 10-04-2012 |
20120251514 | MODULATED PROGRAMMED DEATH LIGAND-1 - The invention provides nucleic acids comprising a nucleotide sequence encoding programmed death ligand-1 (PD-L1) and a nucleotide sequence encoding a fusion protein comprising thymidylate kinase (TMPK) or a variant thereof and a cell surface marker or a variant thereof. Recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and kits relating to the nucleic acids are disclosed. Methods of treating or preventing a disease in a host and methods of suppressing an immune system in a host are also disclosed. | 10-04-2012 |
20120258085 | Expansion of NK Cells - A method of large scale expansion and simultaneous activation of NK cells and NK-like T cells in a closed cell culture system is presented, wherein the expanded cells exhibit increased cytotoxicity. | 10-11-2012 |
20120282234 | Medium, Solutions And Methods For The Washing, Culturing And Storage Of White Blood Cells - White blood cell products and storage media for white blood cells are disclosed. The storage medium includes sodium chloride, sodium acetate, sodium citrate, sodium phosphate, magnesium chloride, potassium chloride, sodium bicarbonate, and glucose. White blood cells stored in such medium remain viable for at least up to 72 hours. | 11-08-2012 |
20120282235 | IMPLANTABLE PATCH AND SURGICAL KIT FOR PREPARATION THEREOF - Embodiments of the present invention include a surgical kit for preparation of a patch for implantation into a human body, characterized in that it comprises a package containing, on one hand, a synthetic substrate ( | 11-08-2012 |
20120288484 | CELLS, COMPOSITIONS AND METHODS - Method of producing induced T-to-Natural-Killer [ITNK] cells, target T cells and/or target pro-T cells from T cells and/or pro-T cells which method involves modulating the activity and/or effect of at least one Bcl11b gene and/or protein present in a T cell and/or pro-T cell, and converting said T cell and/or pro-T cell to an ITNK cell or target Tcells and/or target pro-T cells is described. ITNK cells, target T cells and/or target pro-T cells produced by such method and mature activated T cells in which Bcl11b expression is downregulated or absent, and the use of such cells or modulators of Bcl11b in medicine is also described. | 11-15-2012 |
20120315259 | METHOD AND COMPOSITION FOR SKIN CARE COMPRISING CORD BLOOD SERUM OR PLASMA OR COMPONENTS THEREOF - A method and composition for treating dermatological conditions and improving skin condition and helping hair to grow or thicken involves removing extracts including beneficial secretions from mesenchymal stem cells or other cells with regenerative properties to use itself or components thereof alone or with other skin or hair care reagents as a topical ointment or formula to apply to the skin or hair topically for therapeutic and cosmetic purposes. | 12-13-2012 |
20120328587 | Method for Activating Natural Killer Cells by Tumor Cell Preparation In Vitro - The present invention provides a method for activating a Natural Killer (NK) cell by contacting the NK cell in vitro with an activating tumour cell preparation (ATCP). The invention also provides an activated NK cell produced by such a method and its use in the treatment of cancer. | 12-27-2012 |
20130011375 | T CELL RECEPTORS SPECIFIC FOR IMMUNODOMINANT CTL EPITOPES OF HCV - The present invention relates generally to the field of immunology. More particularly, aspects of the invention concern the discovery of several T cell receptors (TCRs) that are specific for an immunodominant CTL epitope of hepatitis C virus (HCV). Embodiments include TCRs, DNAs encoding TCRs, methods of making TCRs, and methods of using TCRs to treat, prevent or inhibit hepatitis C virus (HCV) proliferation. | 01-10-2013 |
20130011376 | Methods for Enhancing Natural Killer Cell Proliferation and Activity - Methods of ex-vivo culture of natural killer (NK) cells are provided and, more particularly, methods for enhancing propagation and/or functionality of NK cells by treating the cells with a nicotinamide or other nicotinamide moiety in combination with cytokines driving NK cell proliferation. Also envisioned are compositions comprising cultured NK cells and therapeutic uses thereof. | 01-10-2013 |
20130017180 | PLATELET RICH PLASMA FORMULATIONS - Compositions for platelet rich plasma (PRP) and neutrophil-depleted PRP are provided. Methods for treating ischemia damaged tissues by delivering a PRP composition, in some embodiments a neutrophil-depleted PRP composition to the damaged tissue are provided. In some variations, the compositions may be useful to treat ischemic heart disease and repair damaged cardiovascular tissue following acute myocardial infarction including congestive heart failure. In some variations, the compositions may be useful to reduce cardiac apoptosis after a heart attack. | 01-17-2013 |
20130034528 | NEW METHODS FOR ISOLATING TR1 CELLS - The present invention relates to methods for isolating Tr1 cells, resting Tr1 cells and/or activated Tr1 cells, to methods for enriching or depleting a cell population in Tr1 cells, resting Tr1 cells and/or activated Tr1 cells and to methods and kits for treating chronic inflammatory diseases, autoimmune diseases, allergic diseases, cancer and organ transplantation conditions. | 02-07-2013 |
20130045191 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 02-21-2013 |
20130052174 | CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHODS FOR THE PREPARATION AND USES THEREOF - There is provided inter alia a method for the preparation and/or generation of immunomodulatory cells which comprises contacting a mesenchymal stem cell (MSC) and/or fibroblast cell population with peripheral blood leukocytes for between about 2 hours and about 25 days. | 02-28-2013 |
20130058909 | METHODS OF TREATMENT USING EX VIVO EXPANSION OF CORD BLOOD T CELLS - Provided are methods of enhancing ex vivo proliferation of a T cell population, the methods comprising contacting the T cell population with IL-7 and anti-CD3/CD28 antibody to activate and expand the T cell population. Further provided are methods of generating an antigen-specific cytotoxic T cell population comprising priming a CD3/CD28-expanded T cell population against an antigen (e.g., a cancer cell) in the presence of at least one of IL-7, IL-12, and IL-15, or a combination thereof. Further provided are methods of treating T cell lymphopenia in a subject, comprising administering a CD3/CD28-expanded T cell population to the subject. | 03-07-2013 |
20130064802 | METHODS, COMPOSITIONS, AND ASSAYS FOR DETERMINING THE EFFECT OF AN IMMUNE CELL ON A CELL FROM AN INFECTIOUS OR NEOPLASTIC DISEASE - An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. Also provided is an in vitro assay for determining the effect of an activated CD8 | 03-14-2013 |
20130078226 | METHOD FOR RECONSTRUCTING IMMUNE FUNCTION USING PLURIPOTENT STEM CELLS - According to the present invention, there are provided a method for producing a human T cell, which comprises the steps of inducing an iPS cell from a human T cell, and differentiating the iPS cell into a T cell; a pharmaceutical composition comprising the T cell produced by the method; and a method for cell-based immunotherapy using the method. | 03-28-2013 |
20130101567 | Methods to Expand a T Regulatory Cell Master Cell Bank - Compositions and methods for expanding natural T regulatory cells (nTregs) without substantially sacrificing suppressive function of the cells are disclosed. Also provided are uses of the expanded nTregs for cellular therapy. | 04-25-2013 |
20130101568 | IL-13 PRODUCING TR1-LIKE CELLS AND USE THEREOF - The present invention relates to an isolated Tr1-like cell population capable of producing IL-13, the population having immunosuppressive activities; methods for identifying/isolating/enriching the population and its uses thereof. | 04-25-2013 |
20130108602 | METHODS AND USES OF NUR77 AND NUR77 AGONISTS TO MODULATE MACROPHAGES AND MONOCYTES, AND TREAT INFLAMMATION, INFLAMMATORY DISEASE AND CARDIOVASCULAR DISEASE | 05-02-2013 |
20130115200 | Cell Therapy - Dextran sulfate is used in order to reduce pulmonary uptake of intravenously injected Dextran sulfate is capable of reducing the pulmonary uptake of the intravenously injected cells to the levels obtained for intraarterial injection of the cells but without the accompanying risks and side effects of using intraarterial cell injection. The dextran sulfate can therefore be used in a composition together with tumor infiltrating T-lymphocytes to treat metastatic cancer in a subject. | 05-09-2013 |
20130121979 | METHOD OF TREATING CANCER USING PLATELET COMPOSITIONS - Platelets are concentrated from the blood of a patient. The platelets are unactivated or are treated by a method such as ultrasound or agitation to obtain platelet releasate. The platelets are formulated into an injectable formulation which is administered to the same patient the platelets were extracted from in order to treat the patient's cancer. | 05-16-2013 |
20130129696 | Human Stem Cell Materials and Methods - Monocyte derived adult stem cells (MDSCs) isolated from peripheral blood of mammals is provided, along with pharmaceutical compositions containing an MDSC, kits containing a pharmaceutical composition, and methods of preparing, propagating and using MDSCs or differentiated derivatives thereof The uses of these biological materials include methods of treating disorders or diseases, as well as methods of ameliorating a symptom associated with any such disorder or disease. | 05-23-2013 |
20130142766 | PRODUCTION METHOD FOR CELL POPULATIONS - The present invention addresses the problem of providing cell populations having a high proportion of CD4-positive naive T cells and/or CD4-positive central memory T cells, and a production method thereof. The present invention provides a production method for CD4-positive T cell populations which is characterized by using anti-CD3 antibodies, fibronectin fragments, and Interleukin-4. The method is characterized not only by the attainment of a cell group with a high proportion of CD4-positive naive T cells and/or CD4-positive central memory T cells, but also by a high bulk yield. | 06-06-2013 |
20130164272 | METHODS OF IDENTIFYING CENTRAL MEMORY T CELLS AND OBTAINING ANTIGEN-SPECIFIC T CELL POPULATIONS - The invention provides a method of obtaining a population of antigen-specific T cells comprising: (i) dividing PBMCs from peripheral blood of a host into more than one sub-population; (ii) contacting the PBMCs of each sub-population with an antigen; (iii) obtaining a sample of the contacted PBMCs from each sub-population; (iv) measuring the quantity of 1) IL-2 mRNA and 2) IFN-γ mRNA expressed by the PBMCs of each sample; (v) determining the IL-2 index of each sample; (vi) identifying one or more samples with an IL-2 index determined in (v) of greater than or equal to about 10 to identify one or more antigen-reactive, central memory T cell sub-populations; (vii) dividing the antigen-reactive, central memory T cell sub-population(s) identified in (vi) into microcultures; (viii) identifying one or more antigen-reactive microcultures; and (ix) expanding the microculture(s). | 06-27-2013 |
20130195825 | Cells expressing Th1 characteristics and cytolytic properties - A novel cell type has been generated that has both Th1 characteristics and cytolytic activity. These Th1/killer cells are CD4+ cells purified from peripheral blood and manipulated to have Th1 characteristics such as production of IFN-gamma combined with cytolytic activity similar to cytotoxic T-cells (CTL). The CTL activity is targeted toward diseased cells, not normal cells. The cytolytic activity of the Th1/killer cells is mediated by Granzyme B-Perforin mechanism and results in apoptotic death of diseased cells. Methods of producing and using these Th1/killer cells include isolating CD4+ cells from peripheral blood, activating the CD4+ T-cells to form Th1/killer cells and administering these Th1/killer cells with the cytolytic activity to a patient wherein the Th1/killer cells are allogeneic to the patient. | 08-01-2013 |
20130209430 | METHODS FOR REGULATION OF STEM CELLS - Methods are provided for increasing stem cells, hematopoietic progenitor/stem cells, mesenchymal progenitor/stem cells, mesodermal progenitor/stem cells, muscle progenitor/stem cells, or neural progenitor/stem cells in vivo in a mammalian subject. Methods are also provided for treating an immune related disease, a mesenchymal/mesoderm degenerative disease, or a neurodegenerative disease in a mammalian subject in need thereof. | 08-15-2013 |
20130230499 | CELLULAR BLOOD MARKERS FOR EARLY DIAGNOSIS OF ALS AND FOR ALS PROGRESSION - The present invention provides methods for early diagnosis of amyotrophic lateral sclerosis (ALS) and for determining the efficacy of a treatment for ALS in an ALS patient, i.e., monitoring ALS progression, utilizing cellular blood markers; as well as kits for carrying out these methods. | 09-05-2013 |
20130273017 | METHODS AND PRODUCTS FOR TISSUE REPAIR - Methods and devices for the repair of articular tissue using collagen material are provided. Compositions of collagen material and related kits are also provided. | 10-17-2013 |
20130287750 | METHOD OF SELECTING STEM CELLS AND USES THEREOF - A method of selecting stem cells from a heterogeneous population of cells is disclosed. The method comprises contacting the population of cells with an apoptosis inducing agent under conditions which are apoptotic to non-stem cells and non-apoptotic to stem cells, thereby selecting the stem cells from the heterogeneous population of cells. The selected stem cells may then be used for a variety of applications including transplantation and differentiation. | 10-31-2013 |
20130287751 | METHOD FOR DEVELOPING NATURAL KILLER CELLS FROM STEM CELLS - A method for producing NK cells from pluripotent stem cells, which includes culturing pluripotent stem cells in a first serum-free medium, aggregating the undifferentiated stem cells to form embryoid bodies, which are cultured to produce hematopoietic precursor cells, and culturing the precursor cells in a serum-free medium to produce the NK cells. Methods for using such NK cells, e.g., in the treatment of cancer and infectious disease are also provided. | 10-31-2013 |
20130287752 | UNIVERSAL ANTI-TAG CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AND METHODS OF TREATING CANCER - The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αFITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of αFITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer. | 10-31-2013 |
20130302300 | B AND T LYMPHOCYTE ATTENUATOR MARKER FOR USE IN ADOPTIVE T-CELL THERAPY - BTLA-positive (“BTLA+”) lymphocyte signaling drives T cells and kills tumors. BTLA functions as a positive modulator of anti-tumor (anti-melanoma) T cell responses, The BTLA+ T cell responds against tumor or cancer cells, and, in cancer patients respond better to IL-2 than BTLA-negative cells. Hence, the BTLA-positive T cell in cancers is a positive marker for selection of enriched anti-tumor-cancer reactive T cells and can be used or applied for adoptive T-cell therapy or for therapeutic purposes. | 11-14-2013 |
20130302301 | ANTIBODY AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES - The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments. Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR. Anti-αβ TCR antibodies produced by the hybridomaTOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided. The present invention also provides methods of treating inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using a therapeutic amount of ex vivo expanded regulatory T-cells. | 11-14-2013 |
20130302302 | DENDRITIC CELLS HAVING ENHANCED YO T-CELL ACTIVATING AND/OR PROLIFERATING ACTIVITY AND METHODS OF PREPARATION OR USE THEREOF - A therapeutic method, which includes administering dendritic cells pulsed in vitro with a bisphosphonate-based bone metabolism improving drug, is provided. The dendritic cells may be capable of efficiently activating and/or proliferating γδ T-cells in vivo and/or in vitro. This can permit for easy proliferation of γδ T-cells without burdening a patient, leading to practical applications of immune cell therapies that utilize γδ T-cells. | 11-14-2013 |
20130309213 | COMPOSITION AND METHOD FOR IMMUNOLOGICAL TREATMENT OF CANCER, PREVENTION OF CANCER RECURRENCE AND METASTASIS, AND OVERCOMING IMMUNE SUPPRESOR CELLS - Methods for the ex vivo generation of cells of the innate (NKT cells and NK cells) and adaptive (T cells) immune systems for use in adoptive cell transfer (ACT) are provided. The NKT cells render T cells resistant to immune suppression (e.g. they are resistant to the effects of myeloid-derived suppressor cells (MDSCs)). The method involves culturing disease-primed immune cells (obtained from a cancer patient or from a patient with an infectious disease) with i) byrostatin and ionomycin (B/I) to activate and differentiate the cells; followed by sequentially culturing the cells with a) a combination of IL-7 and IL-15 and then b) IL-2, to further differentiate the cells and to render them immune resistant. The resistant immune cells are used to treat and prevent cancer and infectious diseases. | 11-21-2013 |
20130315884 | METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY - Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections. | 11-28-2013 |
20130330310 | EX VIVO DEVELOPMENT, EXPANSION AND IN VIVO ANALYSIS OF A NOVEL LINEAGE OF DENDRITIC CELLS - Disclosed herein are new methods of producing a novel line of dendritic cells. The method comprises subjecting a sample of hematopoietic stem/precursor cells to a first feeder culture system that is supplemented with a first set of factors and a second feeder culture system supplemented with a second group of factors. The disclosure also pertains to new cell types that may be used as cancer immunotherapy. | 12-12-2013 |
20130330311 | ANTIGEN-PRESENTING PLATELETS AND METHODS OF ELICITING AN IMMUNE RESPONSE - Provided herein are methods of producing an antigen-presenting platelet. Also provided herein are methods of eliciting an immune response in a subject using the antigen-presenting platelets described herein. Also provided are methods of screening for an immune response elicited by an antigen-presenting platelet. Further provided are isolated populations of platelets that present a selected antigen produced by the methods described herein. | 12-12-2013 |
20140004091 | Activated Leukocyte Composition and Uses For Wound Healing | 01-02-2014 |
20140010794 | Formulation and Method for Preparing Specific T Cell, and Method for Preparing the Formulation - The present invention provides a formulation and method for preparing specific T cells, and a method for fabricating the above formulation is also disclosed. The formulation can induce specific T cell responses and comprises at least a cell population of dendritic killer cells presenting specific antigens. In addition, the method mentioned above for preparing specific T cells comprises following steps. A cell population of T cells is provided at first. And then, a formulation of preparing specific T cells is added to mix with the cell population of T cells. After cultivating, the specific T cells are harvested. Furthermore, the method for fabricating the above formulation comprises the following steps. First, a cell population of dendritic killer cells is provided. A target sample is then provided, and a step of making the cell population of the dendritic killer cells co-cultivate with the target sample is performed. After co-cultivating, a cell population of dendritic killer cells presenting specific antigens is harvested. | 01-09-2014 |
20140017218 | Method for Inducing Immune Tolerance Using Viable Polymer-Modified Allogeneic Leukocytes - This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, two allogeneic leukocyte populations are contacted (in vivo, in vitro or ex vivo) and one of these leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition. Cellular-based preparations and processes for achieving cellular therapy are also provided. | 01-16-2014 |
20140023626 | Enhancement of Natural Killer (NK) Cell Proliferation and Activity - Methods of ex-vivo culture of natural killer (NK) cells are provided and, more particularly, methods for enhancing propagation and/or functionality of NK cells by treating the cells with an aryl hydrocarbon antagonist in combination with cytokines driving NK cell proliferation. Also envisioned are compositions comprising cultured NK cells and therapeutic uses thereof. | 01-23-2014 |
20140037606 | CELL-BASED, ANTI-CANCER VACCINES - The present invention relates to cancer vaccines and more particularly to compositions and methods for producing activated antigen presenting cells (dendritic cells, macrophages, monocytes, or other cells capable of presenting antigen to T lymphocytes); to pharmaceutical compositions including such cells; and to methods of using such cells (e.g., in treating patients who are suffering from or at risk of developing cancer). | 02-06-2014 |
20140037607 | CULTURE MEDIUM AND METHOD FOR OBTAINING A POPULATION OF TOLEROGENIC DENDRITIC CELLS - The present invention relates to a culture medium suitable for inducing dendritic cell differentiation comprising an effective amount of secretory immunoglobulins A (SIgA) and also to a method for obtaining a population of tolerogenic dendritic cells from cells, in particular monocytes. The present invention relates to uses of tolerogenic dendritic cells thus obtained in therapy and in induction of transplant tolerance. | 02-06-2014 |
20140044686 | MOLECULAR MARKER FOR CANCER STEM CELL - A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker. | 02-13-2014 |
20140044687 | METHOD FOR USING REGULATORY T CELLS IN THERAPY - A method of regulatory cell therapy for a treating a patient in need thereof, wherein 10 | 02-13-2014 |
20140044688 | METHODS FOR SEPARATING CONSTITUENTS OF BIOLOGIC LIQUID MIXTURES - Centrifuges are useful to, among other things, remove red blood cells from whole blood and retain platelets and other factors in a reduced volume of plasma. Platelet rich plasma (PRP) can be obtained rapidly and is ready for immediate injection into the host. Embodiments may include valves, operated manually or automatically, to open ports that discharge the excess red blood cells and the excess plasma while retaining the platelets and other facts. Highs speeds used allow simple and small embodiments to be used at the patient's side during surgical procedures. The embodiments can also be used for the separation of liquids or slurries in other fields such as, for example, the separation of pigments or lubricants. | 02-13-2014 |
20140050710 | METHODS FOR PREPARING ACCESSORY CELLS AND USES THEREOF FOR PREPARING ACTIVATED NK CELLS - The present invention relates to a method for preparing accessory cells, said accessory cells may themselves be used for preparing activated NK cells that may be used in various therapeutic protocols (e.g. cancer treatment). More particularly, the present invention relates to a method for preparing an accessory cell comprising the steps consisting of i) providing a cell and ii) inhibiting in said cell the expression of a gene encoding for a Killer-Cell Immunoglobulin-like Receptor(s) (KIR) ligand. | 02-20-2014 |
20140065117 | METHODS FOR PRODUCING AND USING REJUVENATED RED BLOOD CELLS - Methods for treating blood. The methods comprise obtaining whole blood from a donor, mixing the whole blood with a red blood cell enhancement composition, and incubating the mixture of whole blood and red blood cell enhancement composition. The method can be performed at a time proximate to the time of obtaining blood from the donor, or after the blood has been stored for a period of time. The method rejuvenates red blood cells. | 03-06-2014 |
20140065118 | METHODS OF EXPANDING AND ASSESSING B CELLS AND USING EXPANDED B CELLS TO TREAT DISEASE - Provided herein are methods of expanding B cells, and in particularly B10 cells capable of producing IL-10, ex vivo. The methods include incubation of harvested B cells in the presence of IL-21. Compositions comprising the ex vivo expanded B cells and methods of using the expanded B cell-containing compositions to treat diseases or conditions are also provided. Methods of assessing B10 cell function in a subject are also provided. | 03-06-2014 |
20140072545 | GENERATION OF NATURAL KILLER CELLS AND LYMPHOID TISSUE INDUCER-LIKE (LTI-LIKE) NK-22 CELLS - The present invention relates generally to methods to prepare NK and LTi-like, NK22 cells from HSCs and uses of those cells. | 03-13-2014 |
20140079678 | Method for Activating Natural Killer Cells by Tumor Cell Preparation In Vitro - The present invention provides a method for activating a Natural Killer (NK) cell by contacting the NK cell in vitro with an activating tumour cell preparation (ATCP). The invention also provides an activated NK cell produced by such a method and its use in the treatment of cancer. | 03-20-2014 |
20140086888 | EBV-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE TREATMENT OF LOCOREGIONAL NASOPHARYNGEAL CARCINOMA (NPC) - The present invention concerns methods and compositions for treatment of locoregional nasopharyngeal carcinoma utilizing EBV-specific T cells. In specific embodiments, locoregional solid tumors are treated with cytotoxic T lymphocytes specific for at least one EBV antigen, such as LMP2, LMP1, and/or EBNA1, for example. | 03-27-2014 |
20140086889 | METHOD FOR EXPANDING CD4+CD25+T REGULATOR CELLS - A method for generating/expanding in vitro a CD4 | 03-27-2014 |
20140086890 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS - This invention generally relates to a composition comprising an enriched NK cell population. The invention further relates to a method of treating a solid tumor or a hyperproliferative disorder by administering the enriched NK cell population to a mammalian subject in need thereof. | 03-27-2014 |
20140093488 | TUMOR SUPPRESSION USING HUMAN PLACENTAL PERFUSATE AND HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS - Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. | 04-03-2014 |
20140099292 | CD14+ Cell Compositions and Methods of Using Same - The present invention provides CD 14 | 04-10-2014 |
20140112898 | UNIQUE POPULATION OF REGULATORY T CELLS THAT REGULATE TISSUE REGENERATION AND WOUND HEALING - A unique type of regulatory T cell has been identified in muscle. These tissue-regenerative Treg cells play a role in regulating wound healing. These cells, as well as agents that control their differentiation and/or activity and agents produced by the cells, can be used to modulate wound healing and the differentiation of muscle cells. | 04-24-2014 |
20140120072 | METHOD FOR AMPLIFYING NK CELLS - A technique is needed which can amplify NK cells in vitro and prepare optimum number of NK cells for the adoptive immunotherapy. | 05-01-2014 |
20140127177 | Methods of Manufacture of Therapeutic Products Comprising Vitalized Placental Dispersions - This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 05-08-2014 |
20140134145 | METHOD TO INDUCE AND EXPAND THERAPEUTIC ALLOANTIGEN-SPECIFIC HUMAN REGULATORY T CELLS IN LARGE-SCALE - Methods for inducing, expanding, and/or generating alloantigen-specific regulatory T cells. Alloantigen-specific regulatory T cells can be induced, expanded, and/or generated from naive CD4 | 05-15-2014 |
20140154227 | CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USES - The present invention provides a population of mesenchymal cells that do not express the cell surface markers CD112 and/or CD155 for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues. | 06-05-2014 |
20140154228 | ANTIGEN-SPECIFIC CENTRAL-MEMORY T CELL PREPARATIONS HAVING HIGH CD4+ FRACTION - The invention relates to a method for generation of T cell preparations that are specific for at least one target antigen, comprising the steps of expanding lymphoid cells in vitro in the presence of a target antigen or peptide fragments thereof in an expansion step, isolating cells that secrete interferon gamma and culturing, the cells in the presence of interleukin 2 and interleukin 7 and either an inhibitor of the mTOR Complex 1, or in the presence of an inhibitor of IL-2/IL-2R interaction. The invention further relates to preparations obtained by the method of the invention. | 06-05-2014 |
20140161782 | AUGMENTATION OF CELL THERAPY EFFICACY INCLUDING TREATMENT WITH ALPHA 1-3 FUCOSLYTRANSFERASE - Disclosed are methods, compositions of matter, and kits useful for augmentation of cells through modification of cellular membrane properties following ex vivo treatment. | 06-12-2014 |
20140178348 | Methods using DNA methylation for identifying a cell or a mixture of cells for prognosis and diagnosis of diseases, and for cell remediation therapies - Methods using DNA Methylation arrays are provided for identifying a cell or mixture of cells and for quantification of alterations in distribution of cells in blood or in tissues, and for diagnosing, prognosing and treating disease conditions, particularly cancer. The methods use fresh and archival samples. | 06-26-2014 |
20140186319 | NOTCH INDUCED NATURAL KILLER CELL GENERATION AND THERAPEUTIC USES - A method of preparing differentiated NK cells by ex vivo expansion includes the steps of; (1) isolating a plurality of CD34 | 07-03-2014 |
20140193385 | Method for stimulating a host immune system - A method of manipulating allogeneic cells for use in allogeneic cell therapy protocols is described. The method provides a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism called the “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect. The effectiveness and widespread application of the anti-tumor GVT effect is limited by the severe toxicity of the GVH effect. In the present invention, the anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect. The highly activated allogeneic cells of the invention can be used in methods to stimulate host immunity. The method includes a complete HLA mis-matched setting in patients that have not had a prior bone marrow transplant or received chemotherapy and/or radiation conditioning regimens. | 07-10-2014 |
20140212397 | METHODS FOR REJUVENATING RED BLOOD CELLS - Methods for transfusing blood to a mammalian subject. The method includes obtaining a unit of blood, rejuvenating the blood with an enhancement composition, measuring 2,3-DPG concentration of the blood, and delivering the blood to a subject. | 07-31-2014 |
20140212398 | ANTI THIRD PARTY CENTRAL MEMORY T CELLS, METHODS OF PRODUCING SAME AND USE OF SAME IN TRANSPLANTATION AND DISEASE TREATMENT - A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype. | 07-31-2014 |
20140219978 | GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein. | 08-07-2014 |
20140219979 | HSP60, HSP60 PEPTIDES AND T CELL VACCINES FOR IMMUNOMODULATION - The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders. | 08-07-2014 |
20140234281 | METHODS FOR ELIMINATING AT LEAST A SUBSTANTIAL PORTION OF A CLONAL ANTIGEN-SPECIFIC MEMORY T CELL SUBPOPULATION - The present invention relates generally to methods for stimulating T cells, and more particularly, to methods to eliminate undesired (e.g., autoreactive, alloreactive, pathogenic) subpopulations of T cells from a mixed population of T cells, thereby restoring the normal immune repertoire of said T cells. The present invention also relates to compositions of cells, including stimulated T cells having restored immune repertoire and uses thereof. | 08-21-2014 |
20140234282 | BETA-LACTAM COMPOUNDS FOR TREATING DIABETES - Compositions and methods comprising ampicillin or salts and derivative thereof for the treatment of delaying the on-set of type I diabetes are provided. | 08-21-2014 |
20140242053 | METHOD FOR USING DIRECTING CELLS FOR SPECIFIC STEM/PROGENITOR CELL ACTIVATION AND DIFFERENTIATION - A method is provided, including obtaining a population of antigen-presenting cells, enriching a population of stem/progenitor cells within a larger population of cells, activating the population of antigen-presenting cells and, following the activating, inducing at least one process selected from the group consisting of: differentiation, expansion, activation, secretion of a molecule, and expression of a marker, by exposing the enriched stem/progenitor cell population to the population of antigen-presenting cells. Other applications are also described. | 08-28-2014 |
20140248248 | HUMAN PROGENITOR T-CELLS - Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described. The human progenitor T cells have the phenotype CD34+CD7+CD1a−CD5− or CD34+CD7+CD1a−CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells by coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4). Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy. | 09-04-2014 |
20140255368 | METHOD OF GENERATING TUMOR-SPECIFIC T CELLS - A method for the expansion of tumor-specific T-cells includes obtaining an enriched population of T-cells from a subject with cancer; and contacting the enriched population of T-cells ex-vivo with: (i) an anti-CD3 antibody, an anti-CD28 antibody, and/or functional fragments thereof, and (ii) a VEGF inhibitor, to activate and expand the T-cells. | 09-11-2014 |
20140271587 | TREATMENT OF INFLAMMATORY RESPIRATORY DISEASE USING BIOLOGICAL SOLUTIONS - Methods and therapeutic compositions for treating respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and devices for administering the therapeutic compositions. Methods for treatment include producing a protein solution, producing a concentrated bone marrow aspirate (cBMA), optionally combining the protein solution and cBMA to form an therapeutic composition, and optionally saturating the autologous therapeutic composition with hydrogen gas, and administering the therapeutic composition to a subject in need thereof. The present methods, compositions and devices are useful for treating COPD and the progression of COPD. | 09-18-2014 |
20140271588 | TREATMENT OF PERIPHERAL VASCULAR DISEASE USING PROTEIN SOLUTIONS - Methods of treating peripheral vascular disease comprising administering a protein solution site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII. The solution may also comprise white blood cells, platelets, concentrated bone marrow aspirate, and combinations thereof. | 09-18-2014 |
20140294792 | T-REG Cell Expansion - This invention relates to methods of expanding T regulatory cells through OX40L and Jagged-1 induced signaling. The methods can be used for treating autoimmune diseases. | 10-02-2014 |
20140294793 | GPR15-MEDIATED HOMING AND USES THEREOF - The present invention is directed to in vitro methods for promoting expression of G-protein coupled receptor 15 (GPR15) on T cells, GPR15+ enriched populations of T cells generated using these methods and compositions thereof, as well as methods of using these T cell populations for therapeutic purposes. | 10-02-2014 |
20140301996 | METHODS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES - The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from | 10-09-2014 |
20140308260 | METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS - The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles. | 10-16-2014 |
20140308261 | HLA-DR7 HY epitope and method for treating leukaemia - This invention concerns HY epitopic polypeptides specifically presented by the HLA-DR7 molecule, a method for preparing these epitopic polypeptides, isolated T-lymphocytes capable of specifically recognizing an epitope from these polypeptides or from a polypeptide comprising the complete sequence of the protein encoded by the RPS4Y gene and presented by the HLA-DR7 molecule expressed on the surface of antigen-presenting cells, a method for preparing these T-lymphocytes, as well as the use of these epitopic polypeptides and these T-lymphocytes as medicaments, in particular for the treatment of cancers of immune cells. | 10-16-2014 |
20140322188 | TOLERIZING TREATMENTS FOR AUTOIMMUNE DISEASE - The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and a compound identified by the methods described herein. The disclosure further relates to methods of treating age-related macular degeneration and uveitis. | 10-30-2014 |
20140348808 | CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHODS FOR THE PREPARATION AND USES THEREOF - The present invention relates to immunomodulatory cells, methods for providing immunomodulatory cells, and therapeutic uses of the cells for the immune modulation of mammals in need thereof. | 11-27-2014 |
20140348809 | COMPOSITIONS AND METHODS FOR GENERATING INTERLEUKIN-35-INDUCED REGULATORY T CELLS - Compositions and methods are provided for generating T cells having a regulatory phenotype from conventional T (T | 11-27-2014 |
20140356339 | SEQUENCE-BASED MEASURES OF IMMUNE RESPONSE - The invention is directed to methods of measuring an immune response by comparing sequence-based clonotype frequency data from successively measured clonotype profiles. In particular, the invention includes immunotherapies of cancers, such as lymphomas, that include sensitive pre- and post-vaccination sequence-based measurements of changes in a patient's immune repertoire, thereby providing a sensitive measure of the likelihood of treatment success. | 12-04-2014 |
20140363411 | HUMAN MONOCYTE SUB-POPULATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM INJURY - A subpopulation of peripheral blood mononuclear cells (PBMCs) that is substantially devoid of CD3 | 12-11-2014 |
20140369983 | ISCHEMIC TISSUE CELL THERAPY - The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina. | 12-18-2014 |
20140369984 | BIOMATERIAL FOR ARTICULAR CARTILAGE MAINTENANCE AND TREATMENT OF ARTHRITIS - The present disclosure provides biomaterials and methods for preventing and minimizing progression of cartilage and/or connective tissue damage. Also provided herein are biomaterials and methods for alleviating and/or reducing the risk for developing arthritis (e.g., osteoarthritis) associated with joint injury and/or joint surgery. | 12-18-2014 |
20140377240 | METHODS AND COMPOSITIONS FOR EXPANDING IMMUNOSUPPRESSIVE T REGULATORY CELLS IN VITRO AND USES THEREOF - Disclosed herein are methods and compositions for expanding T-regulatory cells (“Treg” cells), resulting in “conditioned Treg cells.” Also disclosed herein are methods and compositions useful for modulating an autoimmune reaction and for treating or ameliorating immune-related diseases, disorders and conditions using the conditioned Treg cells. | 12-25-2014 |
20150010519 | PEPMIXES TO GENERATE MULTIVIRAL CTLS WITH BROAD SPECIFICITY - The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7. | 01-08-2015 |
20150023937 | HISTONE DEACETYLASE (HDAC) INHIBITOR UP-REGULATES CAR EXPRESSION AND TARGETED ANTIGEN INTENSITY, INCREASING ANTITUMOR EFFICACY - Embodiments of the invention employ methods and compositions for enhancing potency of immune cells that express one or more therapeutic proteins. In certain cases, the methods modulate expression of a CAR transgene in an immune cell, such as a T cell. Specific embodiments employ the exposure of cells and/or individuals to be treated with the cells with an effective amount of at least one agent that upregulates expression of the therapeutic protein, such as a mitogen, histone deacetylase inhibitor, and or DNA methyltransferase inhibitor. | 01-22-2015 |
20150023938 | METHODS OF USING IL-21 FOR ADOPTIVE IMMUNOTHERAPY AND IDENTIFICATION OF TUMOR ANTIGENS - Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of IL-21 compositions and antigen presenting cells (APCs), the resulting T cell population has an enhanced antigen-specificity, and can be reintroduced into the patient. Methods are also disclosed for identifying tumor antigens by culturing T cell populations exposed to IL-21 compositions and APCs in the presence of tumor material. | 01-22-2015 |
20150023939 | APPARATUS AND METHOD FOR SEPARATING AND CONCENTRATING FLUIDS CONTAINING MULTIPLE COMPONENTS - An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient. | 01-22-2015 |
20150037303 | CELLS, COMPOSITIONS, AND TREATMENT METHODS FOR STIMULATION OF HEMATOPOIESIS - The invention discloses novel methods, compositions of matter, and kits for the treatment of disorders affecting the hematopoietic system. Patients are administered an autologous cellular mixture derived from adipose stromal vascular fraction, said cellular mixture comprising endothelial cells, endothelial progenitor cells, T regulatory cells, monocytes, and hematopoietic stem cells. In one embodiment, treatment is provided for patients suffering from inflammatory disorders including aplastic anemia. | 02-05-2015 |
20150037304 | METHODS AND COMPOSITIONS FOR MODIFICATION OF HLA - Disclosed herein are methods and compositions for modulating the expression of a HLA locus, including cells that lack expression of one or more classic HLA genes but are not targeted by Natural Killer (NK) cells for lysis. | 02-05-2015 |
20150064153 | HIGH EFFICIENCY MICROFLUIDIC PURIFICATION OF STEM CELLS TO IMPROVE TRANSPLANTS - Described herein is a novel, highly efficient system to remove erythrocytes and purify leukocytes would raise the quality of UCB and other transplant grafts, thereby significantly improving patient outcomes. | 03-05-2015 |
20150064154 | ADMINISTRATION OF KYNURENINE DEPLETING ENZYMES FOR TUMOR THERAPY - Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids. | 03-05-2015 |
20150071892 | Activated Immunostimulatory Cell Composition for Therapy of Infection - Methods of making activated immunostimulatory cell compositions, activated immunostimulatory cell compositions, and methods of using those compositions to stimulate therapeutic immune response to infectious organisms are described. | 03-12-2015 |
20150086520 | Cell Compositions and Methods of Using Same - The present invention provides cell compositions and methods of using treating disorders, such as inflammatory disorders, such as atherosclerosis and cardiovascular disease. | 03-26-2015 |
20150093366 | GALECTIN-9-SECRETING CELL, AND PRODUCTION METHOD AND USE OF THE SAME - The object of the present invention is to provide a cell that can exhibit physiological activity based on galectin-9, a method for producing the cell, and use of the cell. In order to achieve the above object, the cell of the present invention contains galectin-9, and the galectin-9 is expressed on a cell surface. | 04-02-2015 |
20150110760 | NKP30 RECEPTOR TARGETED THERAPEUTICS - The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same. | 04-23-2015 |
20150110761 | EXPANSION OF ALLOANTIGEN-REACTIVE REGULATORY T CELLS - The present disclosure relates generally to the manufacture of regulatory T cells (Tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive Tregs ex vivo. Alloantigen-reactive Tregs produced in this way are suitable for the induction and/or maintenance of immunologic tolerance in recipients of allogeneic transplants. | 04-23-2015 |
20150110762 | DELIVERY METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED GENOME ENGINEERING - The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a cell. | 04-23-2015 |
20150118206 | STROMAL CELL THERAPY IN TREATMENT OF RADIATION INJURY - Methods are provided for treating, mitigating or protecting from radiation-induced injury using bone marrow stromal cells expanded in culture, adipose-tissue derived non-adherent stromal cells, or the culture supernatant thereof. | 04-30-2015 |
20150118207 | METHOD FOR PRODUCING NATURAL KILLER CELLS, NATURAL KILLER CELLS PRODUCED THEREBY, AND COMPOSITION FOR TREATING CANCERS AND INFECTIOUS DISEASES CONTAINING THE SAME - The present invention relates to a method for producing natural killer cells (hereinafter, referred to as “NK cells”), NK cells produced thereby, and a composition for treating cancers and infectious diseases containing the same. The present invention provides a method for producing NK cells, which maintain high cytotoxicity and cell viability to exhibit high therapeutic effects against cancers and infectious diseases and can be cultured ex vivo at high efficiency and high concentration. In addition, a culture method which maintains cell concentration at a constant level is used for the production of NK cells, and thus the overgrowth of the cells can be prevented so that the cells can be maintained at an optimal state. Particularly, even when the cells are thawed after freezing, the function of the cells is not impaired, and the NK cells can maintain high cell viability and cytotoxicity. Thus, the NK cells can be easily stored and supplied in a liquid or frozen state without needing an additional treatment process. | 04-30-2015 |
20150118208 | ENHANCED AFFINITY T CELL RECEPTORS AND METHODS FOR MAKING THE SAME - The present disclosure provides methods for generating enhanced affinity T cell receptors by agonist selection of hematopoietic progenitor cells expressing an antigen specific TCRα cultured with stromal cells expressing Delta-like-1 or Delta-like-4, compositions prepared from such methods, and uses of thereof. | 04-30-2015 |
20150118209 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE - Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease. | 04-30-2015 |
20150132272 | COMPOSITIONS AND METHODS FOR DIMINISHING AN IMMUNE RESPONSE - The invention is based upon the discovery that T regulatory type 1 (Tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purity and administer Tr1 cells allows for improved methods of Tr1 therapies for treating a wide variety of diseases and disorders. | 05-14-2015 |
20150139971 | METHOD FOR PREPARING REGULATORY DENDRITIC CELLS - An object of the present invention is to establish a method that enables safe and convenient large-scale preparation of regulatory dendritic cells. The present invention provides a method for preparing regulatory dendritic cells, which comprises culturing cells that can be induced to result in regulatory dendritic cells in the presence of a [1,2,4]triazolo[1,5-a]pyrimidine derivative. | 05-21-2015 |
20150147304 | USE OF PI3K M-TOR AND AKT INHIBITORS TO INDUCE FOXP3 EXPRESSION AND GENERATE REGULATORY T CELLS - The invention relates to a method of inducing Foxp3 expression in a T cell comprising
| 05-28-2015 |
20150299656 | METHODS OF PRODUCING T MEMORY STEM CELL POPULATIONS - Provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating naïve T cells from a mammal, wherein the mammal is not a mouse; b) activating the naïve T cells and expanding the numbers of naïve T cells in the presence of one or more non-specific T cell stimuli, one or more cytokines, and a GSK-3beta inhibitor. Also provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating lymphocytes from a mammal; b) sorting the lymphocytes using flow cytometry into a population comprising a phenotype comprising i) CD95+, CD45RO−, and CCR7+; and ii) CD62L+ or one or more of CD27+, CD28+, CD45RA+, and CD127+ to produce an isolated T memory stem cell population. Further embodiments of the invention provide related cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer. | 10-22-2015 |
20150320798 | Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity - The present invention relates to the field of cancer therapy. More specifically, the present invention provides methods and compositions useful for augmenting anti-tumor immunity. In one embodiment, a method for treating or preventing post-allogeneic transplant relapse in a subject who has received post-transplant cyclophosphamide treatment comprises the steps of (a) obtaining a bone marrow sample from the subject; (b) expanding the marrow infiltrating lymphocytes (MILs) present in the sample; and (c) administering the MILs to the subject. In a specific embodiment, the method significantly reduces the likelihood of developing GVHD. | 11-12-2015 |
20150328260 | BLOOD CELL PREPARATIONS AND RELATED METHODS (GEN 8) - The disclosure provides preparations of cells that are enriched in white blood cells, methods for separating cells into different fractions, and methods for administering the different cell fractions into a recipient subject. | 11-19-2015 |
20150329824 | Z CELLS ACTIVATED BY ZINC FINGER-LIKE PROTEIN AND USES THEREOF IN CANCER TREATMENT - Immune cells (Z cells) activated by zinc finger-like protein that regulates apoptosis (Zfra) and uses thereof in cancer treatment. | 11-19-2015 |
20150342992 | CD11 B[low] MACROPHAGES AND CONDITIONED MEDIA THEREOF FOR TREATING CANCER AND/OR FIBROSIS - A conditioned medium of CD11b | 12-03-2015 |
20150342994 | ICOS Critically Regulates the Expansion and Function of Inflammatory Human Th17 Cells - The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents. | 12-03-2015 |
20150352151 | ACTIVATED LEUKOCYTE COMPOSITION AND USES FOR WOUND HEALING - Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds. | 12-10-2015 |
20150353897 | METHOD OF GENERATING MULTILINEAGE POTENTIAL CELLS - The present invention relates generally to a method of generating cells exhibiting multilineage potential and to cells generated thereby. More particularly, the present invention is directed to an in vitro method of generating mammalian stem cells from CD14 | 12-10-2015 |
20150374754 | EXPANDED NK CELLS - The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment. | 12-31-2015 |
20150376296 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (iCAR). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired. | 12-31-2015 |
20160000755 | COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES - Compositions and methods of enhancing the potency and efficacy of adoptive cell therapy using integrin-ligand stabilizers, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the effector cells ex vivo with agonists or stabilizers having the general Formula (I); methods of treating integrin-expressing cells with such stabilizers to enhance tumor infiltration; and therapeutic methods comprising administering stabilizer or agonist-treated cells to a mammal requiring treatment of solid tumors, hematologic cancers. | 01-07-2016 |
20160000832 | STEM CELLS DERIVED FROM BONE MARROW FOR TISSUE REGENERATION - The invention relates to stems cells derived from bone marrow, and uses thereof in tissue regeneration. | 01-07-2016 |
20160000870 | METHODS AND COMPOSITIONS FOR DELIVERING INTERLEUKIN-1 RECEPTOR ANTAGONIST - Methods, systems, and compositions related to generating and using a solution rich in interleukin-1 receptor antagonist are provided. Methods include contacting a liquid comprising white blood cells with a solid extraction material and stimulating with an electromagnetic field to activate production of interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist can be separated from the solid extraction material. Methods for treating a site of inflammation in a patient include administering the solution rich in interleukin-1 receptor antagonist to the site of inflammation. | 01-07-2016 |
20160010058 | METHODS OF PRODUCING ENRICHED POPULATIONS OF TUMOR-REACTIVE T CELLS FROM TUMOR | 01-14-2016 |
20160017010 | METHODS AND COMPOSITIONS FOR DELIVERING INTERLEUKIN-1 RECEPTOR ANTAGONIST - Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist. | 01-21-2016 |
20160017048 | TARGETING CD138 IN CANCER - Embodiments of the present disclosure concern therapeutic vectors and cells that target certain cancer cells but do not other cells having the same antigen. In specific embodiments, the methods and compositions of the disclosure concern cells having a CD138-specific chimeric antigen receptor whose expression is under the control of environment-specific regulation. In specific embodiments the environment is hypoxia. In some cases, the compositions comprise a suicide gene. | 01-21-2016 |
20160024470 | METHODS AND MATERIALS FOR THE GENERATION OF REGULATORY T CELLS - Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25− T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed. | 01-28-2016 |
20160040127 | USE OF LIGANDS FOR THE PROGRAMMED CELL DEATH RECEPTOR CONJUGATED TO SOLID SUPPORTS FOR THE EXPANSION OF HUMAN REGULATORY T CELLS - Disclosed are methods for isolating, cultivating, and/or cells including regulatory T cells (Tregs). The methods typically include cultivating cells including Tregs in a culture media comprising a ligand for programmed cell death receptor (PD-1) conjugated to a solid support. Suitable ligands may include PD-L1 and suitable solid supports may include magnetic or paramagnetic beads where the methods further include removing the PD-L1/bead conjugates after the Tregs have been isolated, cultured, and/or expanded. | 02-11-2016 |
20160045521 | BIOPHOSPHONATE COMPOUNDS AND GAMMA DELTA T CELL-MEDIATED THERAPY FOR TREATING EPSTEIN-BARR VIRUS-ASSOCIATED DISORDERS - Aminobisphosphonate pamidronate (PAM) can control Epstein-Barr virus (EBV) associated disorders in humanized mice through a Vγ9Vδ2-T-cell dependent mechanism. This suggests a strong potential for a therapeutic approach using PAM to boost human Vγ9Vδ2-T-cell immunity against EBV associated disorders, such as the lymphoproliferative disease (LPD), posttransplant lymphoproliferative disorder (PLPD), Hodgkin's disease, Burkitt's lymphoma, and nasopharyngeal carcinoma (NPC). | 02-18-2016 |
20160045549 | INHIBITION OF CHOROIDAL NEOVASCULARIZATION - Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include applying to macrophages in cell culture an agent that causes upregulation of ABCA1 transporter protein, and administering the macrophages to a subject. The agents include, without limitation, LXR agonists. Administration routes can include, without limitation, intraocular, periocular, and systemic administration. | 02-18-2016 |
20160045550 | Method of Expanding Double Negative T Cells - A method of expanding double negative T cells in culture is described. The method comprises (a) providing a starting sample comprising DN T cells or precursors thereof; (b) substantially depleting CD8 | 02-18-2016 |
20160045551 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - The present invention provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells bearing antigen receptors, which can be chimeric antigen receptors (CARS), which express introduced ligands for immunomodulatory molecules. In particular embodiments, engineered immunoresponsive cells are antigen-directed and resist immunosuppression and/or have enhances immune-activating properties. | 02-18-2016 |
20160046910 | TOLEROGENIC DENDRITIC CELLS, METHOD FOR THEIR PRODUCTION AND USES THEROF - The present invention relates to a tolerogenic dendritic cell population (Tr-DC) capable of generating a population of T cells having regulatory activity, method of production and uses thereof. Furthermore, soluble HLA-G promotes the differentiation of a population of T cells with regulatory activity. | 02-18-2016 |
20160074490 | FORMULATION AND METHOD FOR PREPARING SPECIFIC T CELL, AND METHOD FOR PREPARING THE FORMULATION - The present invention provides a formulation and method for preparing specific T cells, and a method for fabricating the formulation is also disclosed. The formulation can induce specific T cell responses, and comprises at least a cell population of dendritic killer cells presenting specific antigens. In addition, the method mentioned above for preparing specific T cells comprises following steps. A T cell population is provided, and then a formulation of preparing specific T cells is mixing with the T cell population. After cultivating, the specific T cells are harvested. Furthermore, the method for fabricating the above formulation comprises the following steps. First, a cell population of dendritic killer cells is provided. A target sample is then provided, and a step of making the cell population of the dendritic killer cells is co-cultivated with the target sample. After co-cultivating, a cell population of dendritic killer cells presenting specific antigens is harvested. | 03-17-2016 |
20160082042 | USE OF MESENCHYMAL STEM CELL-EDUCATED MACROPHAGES TO TREAT AND PREVENT GRAFT VERSUS HOST DISEASE AND RADIATION-INDUCED INJURY - The present invention relates to methods for treating and preventing graft-versus-host disease (GVHD) and radiation-induced tissue damage or organ failure. More particularly, methods of the present invention comprise administering a therapeutically effective amount of mesenchymal stem cell-educated macrophages (MEMs) to a subject to treat or prevent GVHD, bone marrow failure, radiation-induced tissue damage or organ failure, or a condition associated with aberrant inflammation. | 03-24-2016 |
20160114095 | METHODS AND SYSTEMS FOR COLLECTING MONONUCLEAR CELLS - A method for obtaining MNCs is set forth. The method includes: separating mononuclear cells from a biological fluid that includes red blood cells, plasma and platelets and collecting a targeted number of mononuclear cells in a suspension including plasma and residual red blood cells and platelets; concentrating the separated mononuclear cells; removing plasma from the concentrated mononuclear cells until the amount of residual plasma remaining with the concentrated mononuclear cells reaches a pre-determined volume; and adding a crystalloid solution to the concentrated mononuclear cells. Related apparatus and resultant MNC products are also disclosed. | 04-28-2016 |
20160122715 | GENERATION OF CYTOTOXIC TUMOR SPECIFIC CELL LINES AND USES THEREOF - An in-vitro method of activating T cells is disclosed. The method comprises incubating T cells with pathogenic cells in the presence of a multimeric peptide comprising at least two peptide monomers linked to one another, each of the at least two peptide monomers comprising at least 6 consecutive amino acids from the amino acid sequence as set forth in SEQ ID NO: 1, wherein the at least two peptide monomers are each no longer than 30 amino acids, wherein the multimeric peptide is capable of reducing binding of PLIF to human leukocytes under conditions which allow expansion of the T cells. | 05-05-2016 |
20160152681 | ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS | 06-02-2016 |
20160166612 | Human Monocyte Sub-Population for Treatment of Eye Diseases and Disorders | 06-16-2016 |
20160166614 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 06-16-2016 |
20160175357 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS | 06-23-2016 |
20160184361 | METHOD OF TREATMENT EMPLOYING THERAPEUTIC T CELL PRODUCT FROM MOBILISED DONORS - The present disclosure provides a method of treating a human patient in need thereof with immune reconstitution therapy by administering a therapeutically effective amount of therapeutic T cell population selected and/or expanded from a mobilised blood sample or a mobilised apheresis sample, wherein selection is on the basis of a steady state marker and/or an activation marker optionally followed by expansion, or expansion is in the presence of antigen, such as a viral antigen. It also extends to methods of generating said therapeutic T cell populations and the product obtainable therefrom. | 06-30-2016 |
20160199412 | MODIFIED HEPATITIS POST-TRANSCRIPTIONAL REGULATORY ELEMENTS | 07-14-2016 |
20160250255 | METHODS FOR INDUCTION OF ANTIGEN-SPECIFIC REGULATORY T CELLS | 09-01-2016 |
20160375059 | REGULATORY B CELLS AND THEIR USES - The present invention relates to a phenotypically distinct CD1d | 12-29-2016 |
20160375060 | Methods of Treating Glioblastoma Multiforme by T Cell Therapy - Disclosed herein are methods of treating glioblastoma multiforme (GBM) in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV (cytomegalovirus)-specific T cells. | 12-29-2016 |
20180021379 | METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY | 01-25-2018 |
20180022769 | NOVEL FLUORINE-CONTAINING BISPHOSPHONIC ACID DERIVATIVE AND USE THEREOF | 01-25-2018 |
20190144825 | Methods of Treating Cancer and Infectious Diseases Using Cell Based Therapies | 05-16-2019 |
20190144826 | GENERATION OF CTL LINES WITH SPECIFICITY AGAINST MULTIPLE TUMOR ANTIGENS OR MULTIPLE VIRUSES | 05-16-2019 |
20190144857 | T CELL DIFFERENTIATION AND FUNCTION REGULATION | 05-16-2019 |
20220133788 | BAFF THERAPY TO PROMOTE ANTI-TUMOR IMMUNITY - Anti-tumor immune response are generated by induction of activated B cells to provide costimulatory signals necessary for T cell activation. Certain compositions are combined with anti-immune checkpoint inhibitors to generate a synergistic anti-tumor response. | 05-05-2022 |
20220133789 | GENERATING CIK NKT CELLS FROM CORD BLOOD - Provided herein are methods and customized media compositions for culturing CIK NKT cells. | 05-05-2022 |
20220133790 | MODIFIED IMMUNE CELLS HAVING ENHANCED ANTI-NEOPLASIA ACTIVITY AND IMMUNOSUPPRESSION RESISTANCE - As described below, the present invention features genetically modified immune cells having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft versus host reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells. | 05-05-2022 |
20220133792 | SIGNALING PLATFORMS FOR CHIMERIC ANTIGEN RECEPTOR T CELLS - Chimeric antigen receptors (CARs) are disclosed, along with nucleic acids and vectors encoding, and recombinant cells comprising such CARs and therapeutic compositions containing any of the foregoing. The CARs may comprise mutations that alter CAR expression, cytotoxicity, or cytokine production. Also provided are methods for using recombinant cells comprising these CARs for immunotherapy, e.g., in treating cancer by the administration of a therapeutically effective amount of one or more of the CAR polypeptides, nucleic acids, vectors, and/or immune cells, e.g., human CAR T cells, described herein optionally in combination with other immune and cancer treatments. | 05-05-2022 |
20220133802 | FUSION POLYPEPTIDE FOR IMMUNOTHERAPY - The presently disclosed subject matter provides methods and compositions for enhancing immune responses toward tumor and pathogen antigens. It relates to fusion polypeptide that can be expressed in cells (e.g., immunoresponsive cells comprising an antigen-recognizing receptor) to improve the activity and/or efficiency of the cells. In certain embodiments, the fusion polypeptide comprises an extracellular domain and a transmembrane domain of a co-stimulatory ligand, and an intracellular domain of a co-stimulatory molecule. | 05-05-2022 |